23andMe's founder Anne Wojcicki wins bid for bankrupt DNA testing firm
- 23andMe filed for bankruptcy in March, seeking to sell its business at auction after a decline in consumer demand and a 2023 data breachthat exposed sensitive genetic and personal information of millions of customers.
- 06/13/2025
|
23andMe's founder Anne Wojcicki wins bid for DNA testing firm
- Anne Wojcicki is set to regain control of 23andMe after a nonprofit she controls topped Regeneron's bid for the DNA-testing company.
- 06/13/2025
|
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental Biology Scientific Conference
- Results are from Acurx's ongoing scientific collaboration with Leiden University Medical Center (LUMC) partially under a grant from Health Holland to further study the mechanism of action of DNA pol IIIC inhibitors LUMC highlighted Acurx's new class of promising antimicrobials, ibezapolstat and related analogues Novel chemotype specifically targeting gram-positive bacteria through an unexploited target Ibezapolstat ready to enter pivotal Phase 3 clinical trials for C. difficile Infection (CDI), with no cross resistance reported to date Ibezapolstat has previously been granted FDA QIDP and Fast-Track Designations and has received SME (Small and Medium-sized Enterprise) designation by the EMA STATEN ISLAND, N.Y.
- 06/09/2025
|
Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome
- Treatment restored gene control, extended telomere length beyond healthy levels, reversed muscle and weight loss, reduced oxidative stress, and resulted in 100% survival - highlighting Telomir-1's potential to reverse key hallmarks of aging MIAMI, FL / ACCESS Newswire / June 5, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the "Company," an emerging leader in age-reversal science, today announced compelling new preclinical data demonstrating that its lead candidate, Telomir-1, administered orally, significantly increases telomere length, reverses body weight and muscle loss, and resets cellular aging markers in a validated animal model of Werner Syndrome (WS)-a rare genetic disorder also known as adult-onset progeria. These findings confirm and build upon the Company's previously reported results from a preclinical C.
- 06/05/2025
|
Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025
- STONY BROOK, NY / ACCESS Newswire / May 29, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it will effect a 1-for-15 reverse stock split of its issued and outstanding common stock. The Reverse Stock Split will become effective at 12:01 a.m.
- 05/29/2025
|
Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis
- SAN DIEGO--(BUSINESS WIRE)--Telesis Bio Inc. (OTCMKTS: TBIO), a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundries, today announced a new license agreement with Regeneron Pharmaceuticals, Inc. to deploy Telesis Bio's revolutionary Gibson SOLA™ platform at its R&D core facilities. This will help Regeneron adopt automated, high-throughput, on-demand gene synthesis in their own labs. Using Gibson SOLA at s.
- 05/28/2025
|
Ginkgo Bioworks Announces Appointment of Steven Coen as Chief Financial Officer
- BOSTON , May 21, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA, "Ginkgo" or the "Company"), which is building the leading platform for cell programming and biosecurity, today announced that Mark Dmytruk, the Company's Chief Financial Officer, intends to resign from his role at the Company on May 30, 2025 to accept a position at another organization and Steven Coen, CPA, the Company's Chief Accounting Officer, will become Chief Financial Officer, effective upon Mr. Dmytruk's resignation.
- 05/21/2025
|
23andMe was once worth $6 billion. What's left of the DNA testing startup is being bought for $256 million.
- Regeneron Pharmaceuticals will acquire 23andMe's assets for $256 million, both companies said. 23andMe filed for Chapter 11 bankruptcy earlier this year.
- 05/19/2025
|
23andMe sells its most valuable asset. Regeneron promises keep your DNA private.
- Regeneron said it will continue uninterrupted service of 23andMe's consumer genome services — such as connecting with living relatives with shared DNA — after its purchase closes as expected in the third quarter of this year.
- 05/19/2025
|
Applied DNA Reports Second Quarter Fiscal 2025 Financial Results
- - Therapeutic DNA Production Services Segment (LineaRx) Revenues Up 44% Y/Y, Contributing to a 6% Increase in Total Revenues - - Intra-Quarter Investor Conference Call and Webcast Scheduled for June 3, 2025, at 4:30 PM ET - STONY BROOK, NY / ACCESS Newswire / May 15, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today reported financial results for its second quarter of fiscal 2025 ended March 31, 2025. The Company's Form 10-Q for its fiscal second quarter can be viewed on the SEC Filings page of its Investor Relations website.
- 05/15/2025
|
IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19
- Company's PlaCCine® technology platform demonstrates better durability and other advantages compared to mRNA vaccines
- 05/15/2025
|
Applied DNA to Announce Second Quarter Fiscal 2025 Financial Results on May 15, Schedules Intra-Quarter Investor Update Call for June 3
- STONY BROOK, NY / ACCESS Newswire / May 14, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, will release its financial results for the second quarter of fiscal year 2025 (ended on March 31, 2025) after the close of the U.S. equity markets on Thursday, May 15, 2025. The Company's Form 10-Q for the period will be filed concurrently and available on the SEC Filings page of its Investor Relations website.
- 05/14/2025
|
Twist Bioscience and Ginkgo Bioworks Revise Collaboration
- SOUTH SAN FRANCISCO, Calif. & BOSTON--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that the companies have entered into an updated collaboration renegotiated from a prior contract signed in 2022. Under the terms of the revised three-year $15 million agr.
- 05/08/2025
|
Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2025 Earnings Call Transcript
- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q1 2025 Results Conference Call May 6, 2025 5:00 PM ET Company Participants Daniel Marshall - Sr. Manager, Communications and Ownership Jason Kelly - Co-Founder and Chief Executive Officer Mark Dmytruk - Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Mark Massaro - BTIG Tejas Savant - Morgan Stanley Evie Koslosky - Goldman Sachs Matt Larew - William Blair Brendan Smith - TD Cowen Operator [Call Starts Abruptly] live on air. I'm joined by Jason Kelly, our Co-Founder and CEO; and Mark Dmytruk, our CFO.
- 05/06/2025
|
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q1 Loss, Tops Revenue Estimates
- Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.23. This compares to loss of $3.20 per share a year ago.
- 05/06/2025
|
Ginkgo Bioworks Reports First Quarter 2025 Financial Results
- Ginkgo provides an update on its restructuring, including progress towards its expanded $250 million cost savings target Ginkgo and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems BOSTON , May 6, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2025. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com.
- 05/06/2025
|
Twist Bioscience Spins Out DNA Data Storage as Independent Company
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that the company has spun out its DNA data storage technology application as an independent company, named Atlas Data Storage (“Atlas”). “There are many applications of synthetic DNA with the potential to have an incredible impact on the world. With this spin out, both Twist and Atlas are.
- 05/05/2025
|
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Slides as Market Rises: Facts to Know Before You Trade
- The latest trading day saw Ginkgo Bioworks Holdings, Inc. (DNA) settling at $7.37, representing a -0.14% change from its previous close.
- 04/30/2025
|
Phytolon and Ginkgo Bioworks Boost Natural Food Colors by Hitting Full-Project Milestone, Nearly Tripling the Manufacturing Efficiency of Phytolon's Innovative Colors
- Replacing artificial dyes with natural colors has become a national priority, moved by consumer demand, regulation, and governmental pressure. Achieving this milestone—by increasing coloring efficiency and reducing costs—could unlock new market segments that are not well-supported by current natural food colors.
- 04/30/2025
|
Ginkgo Bioworks Announces Date of First Quarter 2025 Results Presentation
- Presentation and Q&A session scheduled for post-market on Tuesday, May 6, 2025 BOSTON , April 29, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2025, on Tuesday, May 6, 2025, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.
- 04/29/2025
|
Ginkgo Bioworks Holdings, Inc. (DNA) Rises Yet Lags Behind Market: Some Facts Worth Knowing
- In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $7.60, marking a +0.8% move from the previous day.
- 04/23/2025
|
Ginko Automation Partners with Aura Genetics to Accelerate Direct-to-Consumer Testing and Innovation
- BOSTON , April 22, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Ginkgo Automation will design and deploy a Reconfigurable Automation Cart (RAC) system to Aura Genetics, a high-complexity diagnostic laboratory servicing the growing at-home testing and wellness market. This advanced modular laboratory automation platform will be deployed at Aura Genetics' new 22,000-square-foot high-throughput facility at the UPS Healthcare Labport, located at the end of the runway at the Louisville, KY airport.
- 04/22/2025
|
Applied DNA's LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA
- - Pivot to U.S.-based Supply Chain for Critical Input Materials Completed - STONY BROOK, NY / ACCESS Newswire / April 21, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that LineaRx, Inc., the Company's majority-owned subsidiary, has completed a long-term initiative to source critical input materials for its LineaDNA™ and LineaIVT™ platforms from U.S.-based suppliers. The initiative, undertaken in response to the 2024 BIOSECURE Act and customer demand for a U.S.-based supply chain, comes as the biopharmaceutical industry increasingly considers reshoring manufacturing operations to the U.S. in response to potential tariff impacts and to ensure a stable supply chain.
- 04/21/2025
|
Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors
- STATEN ISLAND, N.Y. , April 17, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that a new patent has been granted by the Indian Patent Office in March 2025.
- 04/17/2025
|
Ginkgo Bioworks Teams Up with Partners on ARPA-H Project to Stabilize Pharmaceutical Supply Chains - Using Amber Waves of Grain
- Ginkgo Bioworks and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems BOSTON , April 10, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new contract with the Advanced Research Projects Agency for Health (ARPA-H), alongside partners Tritica Biosciences , US Pharmacopeia (USP), On Demand Pharmaceuticals , and Isolere Bio by Donaldson . This two-year program, Wheat-based High efficiency Enzyme and API Technology (WHEAT), aims to establish a new manufacturing process for the distributed production of biologic and small molecule active pharmaceutical ingredients (APIs) using wheat germ cell-free expression systems.
- 04/10/2025
|
23andMe probe launched to prevent customer DNA data from being sold to China or other bad actors
- Sen. Bill Cassidy is probing 23andMe, which recently filed for bankruptcy protection, to ensure the company does not sell customer data to China or other foreign adversaries.
- 04/09/2025
|
Focus Graphite Advanced Materials Commences Work Program with AETC for C4V Digital DNA(TM) Testing and Strategic Specialty Applications
- Exclusion of Canadian natural graphite from President Trump's "Liberation Day" U.S. Tariffs underscores urgency to fast-track testing and qualification with industry partners. OTTAWA, ON / ACCESS Newswire / April 9, 2025 / Focus Graphite Advanced Materials Inc. (TSXV:FMS)(OTCQB:FCSMF)(FSE:FKC) ("Focus" or the "Company"), is pleased to announce the commencement of its advanced material preparation and testing program in collaboration with U.S.-based Advanced Energy Technologies Corp. ("AETC"), a leading processor of industrial graphite and carbon materials for the upstream and advanced downstream applications.
- 04/09/2025
|
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement
- STONY BROOK, NY / ACCESS Newswire / April 8, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that on April 7, 2025, it received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq"), informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). As previously reported, the Company was notified on November 12, 2024, that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Minimum Bid Price Requirement.
- 04/08/2025
|
What's next for 23andMe and all that DNA data?
- As 23AndMe files for bankruptcy, customers are left wondering what happens to their DNA data? On this episode of the Big Take podcast, we discuss what this means for millions of users' genetic data and for the future of the genetic testing industry.
- 04/06/2025
|
Plex Research Partners With Ginkgo Bioworks on Artificial Intelligence (AI)-Powered Drug Discovery to Identify Novel Disease Mechanisms and Pathways
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Plex Research is partnering with Ginkgo Bioworks to use AI to deepen understanding of the mechanisms of action of existing drugs.
- 04/03/2025
|
Here's Why Ginkgo Bioworks (DNA) is Poised for a Turnaround After Losing -28.84% in 4 Weeks
- The heavy selling pressure might have exhausted for Ginkgo Bioworks (DNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 04/01/2025
|
Applied DNA Positions TR8 PGx Testing Service as Pre-Emptive Testing for Safety of Fluoropyrimidine-Based Cancer Therapeutics Following Publication of Food and Drug Administration Safety Announcement
- - Company Revamps Pharmacogenomics Go-To-Market Strategy, Targets Validated PGx Assay Towards Specific Use Cases - STONY BROOK, NY / ACCESS Newswire / April 1, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that Applied DNA Clinical Labs (ADCL), its wholly-owned clinical laboratory subsidiary, is repositioning its TR8™ PGx pharmacogenomics testing service to offer tailored subpanels for indication-specific use cases in addition to full panel testing. The first subpanel under ADCL's new go-to-market strategy is for the pre-emptive testing of patients with genetic variants of the DPYD gene that correlate to potentially reduced or absent DPD enzyme activity necessary to metabolize fluoropyrimidines, specifically capecitabine (branded Xeloda) and fluorouracil (5-FU), two chemotherapy drugs that are widely used as part of the standard of care treatment for patients with certain cancers.
- 04/01/2025
|
23andMe bankruptcy: With America's DNA put on sale, market panic gets a new form of testing
- The bankruptcy of consumer genetics testing company 23andMe last week led to widespread fears about the DNA of millions of Americans going on sale to the highest bidder. 23andMe has 15 million customers and with calls for users to delete their data, traffic to its website surged 526% on the day of its bankruptcy filing.
- 03/30/2025
|
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
- In the closing of the recent trading day, Ginkgo Bioworks Holdings, Inc. (DNA) stood at $6.59, denoting a -0.9% change from the preceding trading day.
- 03/27/2025
|
24/7 Market News- Kraig Labs Makes History: World Record DNA Insertion Unlocks Massive Potential
- Denver, Colorado--(Newsfile Corp. - March 27, 2025) - 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, reports that Kraig Biocraft Laboratories' (OTCQB: KBLB) ("Kraig Labs") groundbreaking achievement-successfully inserting the largest functional DNA construct ever recorded into silkworms-is set to redefine what's possible in synthetic biology and biotechnology. This technological leap doesn't merely advance the science; it dramatically expands Kraig's potential to deliver next-generation materials and products to multiple high-value markets.
- 03/27/2025
|
23andMe goes bankrupt, will now auction off DNA data
- 23andMe has proposed a May 14 auction for the sale of its assets, which include the genetic data of more than 15 million customers. The sale of genetic data raises concerns about privacy and safety, and customers are worried about what this means for their personal information.
- 03/27/2025
|
Republic Bank Selects DNA From Fiserv to Drive Digital Transformation
- MILWAUKEE--(BUSINESS WIRE)--Fiserv, Inc. (NYSE: FI), a leading global provider of payments and financial services technology, today announced that Republic Bank & Trust Company (Republic Bank) has chosen the Fiserv award-winning DNA® platform to enhance the company's banking system capabilities and drive operational efficiencies to realize their digital transformation goals. With over $6 billion in assets and 47 banking centers, Republic Bank, a community bank headquartered in Louisville, K.
- 03/27/2025
|
Applied DNA Submits Validation Package to New York State Department of Health for H5 Bird Flu/Pan-Influenza A Laboratory-Developed Test
- STONY BROOK, NY / ACCESS Newswire / March 26, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that Applied DNA Clinical Labs (ADCL), the Company's wholly-owned clinical laboratory subsidiary, has submitted a validation package to the New York State Department of Health (NYSDOH) to request approval as a laboratory-developed test (LDT) for a PCR-based assay for the detection and subtyping of influenza A (H5) virus, also known as H5 bird flu, highly pathogenic avian influenza, or H5N1 (collectively "H5 bird flu"). ADCL's Linea™ Avian Influenza H5 Dx assay ("AIH5 Dx") is a highly sensitive, multi-target diagnostic assay capable of detecting and discriminating between pan-influenza A and H5 bird flu.
- 03/26/2025
|
23andMe has filed for bankruptcy. What does this mean for your DNA data privacy?
- The genetic testing company 23andMe has filed for bankruptcy, prompting people who've used the service and sent in DNA samples to be analyzed to wonder what will happen to their genetic data.
- 03/26/2025
|
DNA testing pioneer 23andMe files for bankruptcy as concerns mount over data privacy of 15M customers
- DNA testing pioneer 23andMe filed for bankruptcy — sparking fresh concerns about safeguarding the personal data of the company's more than 15 million customers.
- 03/24/2025
|
DNA testing firm 23andMe files for bankruptcy protection
- DNA testing firm 23andMe has filed for bankruptcy protection in the US, marking the collapse of one of the most high-profile names in consumer genetics. Co-founder Anne Wojcicki has stepped down as chief executive with immediate effect, though she will remain on the board.
- 03/24/2025
|
DNA testing firm 23andMe files for Chapter 11 bankruptcy to sell itself
- Genetic testing firm 23andMe filed for Chapter 11 bankruptcy in the U.S. on Sunday and said it was looking to sell itself.
- 03/23/2025
|
Ginkgo Bioworks Holdings, Inc. (DNA) Surpasses Market Returns: Some Facts Worth Knowing
- Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $7.27, moving +1.39% from the previous trading session.
- 03/21/2025
|
Circulating DNA RNA Patent Landscape Report and Forecast 2024-2032: Nantomics, Genentech, and Novartis are Pivotal in the Development of the $16.4 Billion Market
- Dublin, March 14, 2025 (GLOBE NEWSWIRE) -- The "Circulating DNA RNA Patent Landscape Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering. A newly revealed comprehensive overview of the circulating DNA/RNA patent landscape discloses remarkable industry growth projections, with an expected surge from USD 5.32 billion in 2023 to USD 16.4 billion by 2032. The market is advancing at an impressive compound annual growth rate (CAGR) of 13.29%, driven by innovations in nucleic acid-based therapeutics and diagnostics. Patent Landscape Overview The report provides a thorough examination of blood-based biomarkers critical for non-invasive diagnostics in various conditions ranging from cancer to genetic disorders. The increasing number of patents in next-generation sequencing, cancer biomarkers, and therapeutic delivery systems are significantly shaping the industry landscape, propelling advancements in non-invasive diagnostics and personalised medicine. Regional Patent Activity Highlights Insights into the patent activity emphasize the dominance of the United States with over 600 patents, closely pursued by Europe and Asia, with 400 and 250 patents respectively. These regions underscore significant contributions to the industry, each with distinctive advantages in the biotech sector and supportive government initiatives that enhance the competitive position on a global scale. Segmentation Analysis The patent landscape encompasses a myriad of segments, primarily led by the oncology sector with a notable number of filings. Innovations in non-invasive diagnostics and personalised medicine are elucidated, showcasing strategic focus areas for major actors in the field. Furthermore, the in-depth analysis spells out the dynamics within technologies and indications, predicting continued growth and expansion into diverse medical applications. Key Industry Players Prominent market participants such as Nantomics, Genentech Inc., and Novartis AG are pivotal in the development of the circulating DNA/RNA patent landscape. These companies hold substantive patents in detection, analysis, and therapeutic applications of circulating nucleic acids, reinforcing their impact on the overall industry growth and innovation trajectory. Strategic Insights and Future Opportunities The comprehensive analysis of the patent landscape signifies a vibrant and advancing sector, providing strategic insights into industry dynamics and future opportunities. As patents continue to drive the expansion of this domain, stakeholders and industry participants can anticipate new technological frontiers in personalised medicine and non-invasive diagnostic methodologies, ultimately enhancing patient care and healthcare outcomes. This landmark report reflects the propulsive nature of the circulating DNA/RNA sector, offering critical insights that underpin the unfolding narrative of genomic medicine and its expansive potential. Key Attributes:
- 03/14/2025
|
After Plunging -52.33% in 4 Weeks, Here's Why the Trend Might Reverse for Ginkgo Bioworks (DNA)
- The heavy selling pressure might have exhausted for Ginkgo Bioworks (DNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 03/14/2025
|
INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19
- Long-lasting in vivo antibody production: DMAb levels remained stable for 72 weeks in all participants (n=24) who have reached that timepoint No anti-drug antibodies (ADA): no immune rejection of the DMAbs was detected across ~1,000 blood samples, unlike other gene-based antibody delivery approaches where ADA formation has been a challenge Well-tolerated: most common side effects were mild, temporary injection site reactions such as pain and redness; no serious adverse events (SAEs) related to study drug Effective target binding: expressed DMAbs successfully bound to the SARS-CoV-2 Spike protein receptor-binding domain (RBD), confirming functional activity through week 72 PLYMOUTH MEETING, Pa. , March 13, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced promising interim results from an ongoing Phase 1 proof-of-concept trial evaluating DMAbs for COVID-19.
- 03/13/2025
|
Applied DNA Announces 1-For-50 Reverse Stock Split Effective March 14, 2025
- STONY BROOK, NY / ACCESS Newswire / March 12, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that it will effect a 1-for-50 reverse stock split of its issued and outstanding common stock. The Reverse Stock Split will become effective at 12:01 a.m.
- 03/12/2025
|
VW's cheapest EV will have Rivian DNA and who is bidding for Canoo's assets
- Welcome back to TechCrunch Mobility — your central hub for news and insights on the future of transportation. Sign up here for free — just click TechCrunch Mobility!
- 03/06/2025
|
Resilience is part of our DNA, says Merck KGaA CEO
- Belén Garijo, CEO of Merck KGaA, said the German pharmaceutical company has increased its readiness to deal with the ongoing geopolitical uncertainty, and is confident it will continue delivering profitable growth in 2025.
- 03/06/2025
|
Ginkgo Bioworks (DNA) Upgraded to Buy: Here's Why
- Ginkgo Bioworks (DNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 03/05/2025
|
WuXi Biologics Launches EffiX™ Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production
- - EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system.
- 03/03/2025
|
Ginkgo Bioworks: Revenue Struggles Continue
- Ginkgo Bioworks missed Q4 revenue estimates and issued extremely weak 2025 revenue guidance. Despite improving losses and cash burn, financial flexibility is decreasing, with cash reserves dropping significantly over the past year. The company's valuation is low, but declining revenues and high stock-based compensation pose risks.
- 02/27/2025
|
2025 Is Make Or Break For Ginkgo Bioworks
- Ginkgo Bioworks' restructuring has resulted in a dramatic reduction in cash burn in recent quarters. Ginkgo remains a long way from breakeven though and growth is expected to be poor in 2025. Unless Ginkgo can demonstrate continuous progress in 2025, its stock is likely to remain under pressure due to its shrinking cash runway.
- 02/27/2025
|
Flywire Posts Downbeat Results, Joins Lemonade, Ginkgo Bioworks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
- U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Wednesday.
- 02/26/2025
|
IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19
- Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine ® technology
- 02/26/2025
|
Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2024 Earnings Call Transcript
- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q4 2024 Earnings Conference Call February 25, 2025 5:30 PM ET Company Participants Joseph Fridman - Director, Communications and Corporate Affairs Jason Kelly - Founder, CEO & Director Mark Dmytruk - CFO Jason Kelly - Founder, CEO & Director Conference Call Participants Jason Lai - Morgan Stanley Evie Kslosky - Goldman Mark Massaro - BTIG Brendan Smith - TD Cowen Matt Larew - William Blair & Company Joseph Fridman Good evening. I'm Joseph Fridman, Director of Communications and Corporate Affairs here at Ginkgo, where it's my fifth year.
- 02/25/2025
|
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q4 Loss, Misses Revenue Estimates
- Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $1.82 per share versus the Zacks Consensus Estimate of a loss of $1.45. This compares to loss of $3.60 per share a year ago.
- 02/25/2025
|
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financial Results
- Ginkgo provides update on its restructuring process including significant improvement in cash flow in the fourth quarter, completion of site consolidation and an expanded cost savings target Cell Engineering revenue of $35 million in the fourth quarter of 2024, representing 29% growth over 2023 BOSTON , Feb. 25, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the fourth quarter and year ended December 31, 2024. The update, including a webcast slide presentation with additional details on the fourth quarter and full year, as well as supplemental financial information will be available at investors.ginkgobioworks.com.
- 02/25/2025
|
Maravai LifeSciences Completes Acquisition of the DNA and RNA Business of Officinae Bio
- SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that it has completed its previously announced acquisition of Officinae Bio's DNA and RNA business. This acquisition combines Officinae Bio's AI-enabled mRNA design platforms with Maravai and TriLink BioTechnologies' leading drug substance manufacturing capabilities, providing customers comprehensive expertise and n.
- 02/24/2025
|
Ginkgo Bioworks integrates Callisto for difficult-to-automate NGS processes in their high-throughput lab
- BOSTON , Feb. 21, 2025 /PRNewswire/ -- Volta Labs , a leading genomics applications company, and Ginkgo Bioworks, (NYSE: DNA), which is building a leading platform for cell programming and biosecurity, today announced the integration of the Callisto™ Sample Prep System at Ginkgo Bioworks as part of the routine Illumina sequencing workflow. "I like the Apps and the App Store concept on Callisto.
- 02/21/2025
|
Ginkgo Bioworks Partners with HaDEA in Up to €24 Million Consortium Project to Deliver Next-Generation 'Agnostic Diagnostics' for Respiratory Viruses at the Point of Care
- International consortium to develop rapid metagenomic NGS solutions that can identify known and novel respiratory pathogens, reduce time-to-diagnosis, and enhance hospital decision-making and public health preparedness BOSTON , Feb. 20, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a collaboration with the European Health and Digital Executive Agency (HaDEA) as contracting authority under a joint tender of up to €24 million. The funding is made available through the EU4Health programme, linked to the key priorities of the Health Emergency Preparedness and Response Authority (HERA) of the European Commission.
- 02/20/2025
|
JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors
- STATEN ISLAND, N.Y. , Feb. 19, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that a new patent has been granted by the Japanese Patent Office (JPO) in January 2025.
- 02/19/2025
|
Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2024 Results Presentation
- Presentation and Q&A session scheduled for post-market on Tuesday, February 25, 2025 BOSTON , Feb. 18, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2024, on Tuesday, February 25, 2025, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.
- 02/18/2025
|
DNA from Fiserv Selected by Third Federal as Part of its Digital Transformation
- MILWAUKEE--(BUSINESS WIRE)--Fiserv, Inc. (NYSE: FI), a leading global provider of payments and financial services technology, today announced it will deliver digital innovation through the award-winning DNA® platform to Third Federal Savings & Loan. The platform will better equip Third Federal to serve account holders through future-ready technologies and real-time transactions via all channels, propelling customization and growth. Third Federal, a $17bn bank based in Cleveland, selected DN.
- 02/14/2025
|
Applied DNA Reports First Quarter Fiscal 2025 Financial Results and Highlights Operational Progress
- - Announces Exit of DNA Tagging and Security Products and Services Business Segment - - Workforce Reduction of 20% of Headcount Implemented in January - - GMP Site 1 Facility Complete and Certified for Commercial Operation in January - - Webcast and Conference Call Scheduled for today at 4:30 PM ET - STONY BROOK, NY / ACCESS Newswire / February 13, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today reported financial results for its first quarter of fiscal 2025 ended December 31, 2024. The Company's Form 10-Q, once filed, can be viewed on the SEC Filings page of its Investor Relations website.
- 02/13/2025
|
Applied DNA to Report First Quarter Fiscal 2025 Financial Results After Market Close on Thursday, February 13, 2025
- Investor Call and Webcast Scheduled for 4:30 P.M ET STONY BROOK, NY / ACCESS Newswire / February 12, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its first quarter fiscal 2025 financial results after the market close on Thursday, February 13, 2025. The Company will host a conference call for shareholders and the investment community at 4:30 p.m.
- 02/12/2025
|
Applied DNA Reminds Shareholders to Vote Ahead of Special Meeting on February 14
- STONY BROOK, NY / ACCESS Newswire / February 11, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today issued a reminder to its shareholders to vote ahead of a reconvening of a Special Meeting of Stockholders (the "Special Meeting") to be held on Friday, February 14, 2025 at 11:00 a.m. The Company's Board of Directors encourages any shareholder as of the record date of November 25, 2024, who has not yet voted their shares on the Warrant Exercise Proposal (as defined below), to contact Kingsdale Advisors to vote their shares: 1-855-682-9644 or by e-mail at contactus@kingsdaleadvisors.com.
- 02/11/2025
|
Mercado Libre CEO and Founder Marcos Galperin Reflects on the company's 25-Year Journey and DNA in Latest Episode of Inside Mercado Libre
- Montevideo, Uruguay, 6 February 2025, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Mercado Libre (NASDAQ: MELI), the leading e-commerce and fintech platform in Latin America, drops the fifth episode of its podcast series, Inside Mercado Libre, "Marcos Galperin on MELI's Culture” featuring its CEO and founder Marcos Galperin. The Inside Mercado Libre podcast, hosted by Investor Relations Officer, Richard Cathcart, provides investors with unique access to the company executives' strategic views.
- 02/06/2025
|
Strength Seen in Ginkgo Bioworks (DNA): Can Its 14.5% Jump Turn into More Strength?
- Ginkgo Bioworks (DNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 02/06/2025
|
Ginkgo Bioworks to Host 6th Annual Ferment as Boston-based Conference Series
- Evolution of Ferment conference to kick off Summer 2025 BOSTON , Feb. 6, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the 2025 Ferment Series, an evolution of its flagship annual conference dedicated to advancing Ginkgo's mission of making biology easier to engineer. Throughout 2025, Ginkgo product teams will hold a series of focused Ferments at Ginkgo's beautiful event venue, located at 19 Fid Kennedy Ave in Boston's historic Seaport District, just a five-minute walk from Ginkgo's headquarters.
- 02/06/2025
|
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
- DOYLESTOWN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today provided an update on its existing patent portfolio.
- 02/05/2025
|
Ginkgo Bioworks (DNA) Upgraded to Strong Buy: Here's What You Should Know
- Ginkgo Bioworks (DNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- 01/29/2025
|
Genialis Advances Biomarker Discovery to Reduce Risk in Cancer Drug Development Targeting DNA Damage Response Pathways
- BOSTON--(BUSINESS WIRE)-- #ISO27001--Genialis and Debiopharm expand collaboration to develop RNA-based predictive biomarkers for DDR therapies, advancing precision oncology.
- 01/28/2025
|
Ginkgo Automation to Deploy Flexible Laboratory Automation System for Cutting-Edge Biofuels and Bioproducts Research at Great Lakes Bioenergy Research Center (GLBRC)
- Customizable, anaerobic-enabled system aims to accelerate discovery and development of sustainable biofuels at the University of Wisconsin–Madison's GLBRC BOSTON , Jan. 23, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Ginkgo Automation will design and deploy a flexible, anaerobic-enabled laboratory automation system for the Great Lakes Bioenergy Research Center (GLBRC), a U.S. Department of Energy-funded Bioenergy Research Center at the University of Wisconsin–Madison. This new system is designed to support the diverse needs of multiple investigators and research teams simultaneously, enabling GLBRC scientists to more efficiently discover and optimize synthesis of biofuels and bioproducts from plant biomass.
- 01/23/2025
|
Aldevron Unveils Next-Generation Alchemy™ Cell-Free DNA Technology for Research Grade Applications
- FARGO, N.D.--(BUSINESS WIRE)--Aldevron Unveils Next-Generation Alchemy™ Cell-Free DNA Technology for Research Grade Applications.
- 01/21/2025
|
Ginkgo Bioworks Partners with Universal Cells, an Astellas Company, to Advance Next-Generation iPSC-Derived Cell Therapies for Solid Tumors
- Collaboration leverages Ginkgo's cell engineering and screening platform to enhance the potency and persistence of Universal Cells' iPSC-derived immune cell therapeutics BOSTON , Jan. 13, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a research collaboration with Universal Cells, an Astellas company, to optimize next-generation induced pluripotent stem cell (iPSC)-derived cancer cell therapies. This collaboration underscores Ginkgo's capacity to deploy high-throughput biological approaches to tackle the complex challenge set associated with development of therapies targeting solid tumors.
- 01/13/2025
|
Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery
- The Truveta collaboration will extend Regeneron Genetics Center's ® (RGC TM ) world-leading DNA sequence-linked healthcare database (now including almost three million de-identified patient volunteers) through genetic sequencing of up to ten million additional patient volunteers, all with linked electronic health records, creating the Truveta Genome Project
- 01/13/2025
|
Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates
- - Signals Start of New Commercialization Phase for LineaRx Subsidiary - - Company Negotiating GMP Supply Agreement - - Company Reaffirms Strategic Restructuring Timeline - STONY BROOK, NY / ACCESSWIRE / January 10, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the completion of the buildout of its new Good Manufacturing Practices (GMP) manufacturing facility (the "facility") within its Stony Brook, New York, headquarters and readiness to accept orders for the manufacture of LineaDNA™ IVT templates that clients can utilize for the production of mRNA clinical trial materials. The facility is undergoing final testing and is expected to be fully operational by the end of the current month.
- 01/10/2025
|
Rapid Rise of Synthetic Biology Fuels Enzymatic DNA Synthesis Boom Across Biopharma and Genomics
- Dublin, Jan. 09, 2025 (GLOBE NEWSWIRE) -- The "Enzymatic DNA Synthesis Market by Service, by Application, by End-User, and By Region" report has been added to ResearchAndMarkets.com's offering. The global enzymatic DNA synthesis market is estimated to be USD 0.296 billion in 2024 and is expected to reach USD 3.90 billion by 2035, with a CAGR of 26.43% during the forecast period 2025-2035.
- 01/09/2025
|
KBRA Assigns Preliminary Ratings to Freddie Mac's STACR 2025-DNA1
- NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns preliminary ratings to 24 classes from Freddie Mac Structured Agency Credit Risk (STACR®) REMIC 2025-DNA1 Notes, Freddie Mac STACR REMIC Trust 2025-DNA1 (STACR 2025-DNA1), a credit risk sharing transaction with a total note offering of $675,500,000. STACR 2025-DNA1 features loans with loan-to-value (LTV) ratios greater than 60%, but less than or equal to 80%. The Offered Notes represent obligations of the STACR 2025-DNA1 Trust in a credit-linked note stru.
- 01/09/2025
|
Ginkgo Bioworks Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference
- BOSTON , Jan. 9, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Co-Founder and CEO, Jason Kelly, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 10:30 a.m.
- 01/09/2025
|
Applied DNA Reschedules Investor Update Call in Observance of the National Day of Mourning in Recognition of the Passing of Former President Jimmy Carter
- STONY BROOK, NY / ACCESSWIRE / January 8, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it has rescheduled its Investor Update call to Thursday, February 13, 2025, to coincide with the release of its first quarter fiscal 2025 financial results. The Company originally scheduled an Investor Update call for January 9, 2025, to update shareholders on its strategic restructuring announced in December 2024 and GMP initiative.
- 01/08/2025
|
Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA
- - Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies - STONY BROOK, NY / ACCESSWIRE / December 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, announced that the State Institute for Drug Control of the Czech Republic (SÚKL) approved an application for a Phase I clinical trial of an investigational CD123-specific autologous CAR T-cell therapy by the Institute of Hematology and Blood Transfusion (ÚHKT/Eng: IHBT) in Prague for the treatment of relapsed and/or refractory acute myeloid leukemia (AML). UHKT-CAR123-01 utilizes Applied DNA's synthetic DNA, Linea™ DNA, as a critical component in its manufacture.
- 12/18/2024
|
Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines
- - Pursuing Divestiture of CertainT® Platform, Implements Changes to Corporate Leadership - - Build-out of GMP Manufacturing Facility to be Completed by January 9, 2025 - - Webcast and Conference Call Scheduled for Thursday, January 9, 2025, at 4:30 PM ET - STONY BROOK, NY / ACCESSWIRE / December 17, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today reported financial results for its fourth quarter and fiscal year ended September 30, 2024. An update on the buildout of the Company's GMP manufacturing facility is available for viewing via slideshow on the Presentations page of the Investor Relations portion of the Company's website.
- 12/17/2024
|
All You Need to Know About Ginkgo Bioworks (DNA) Rating Upgrade to Buy
- Ginkgo Bioworks (DNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 12/17/2024
|
Ginkgo Bioworks Awarded $9.4 Million in Partnership with Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under ARPA-H's REACT Program
- Ginkgo Bioworks to apply its mammalian cell engineering expertise to develop new cell-based systems for treating and monitoring endocrine disorders BOSTON , Dec. 17, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a subcontract of up to $9.4 million awarded in partnership with Carnegie Mellon University to develop bioelectronic cell-based devices aimed at diagnosing and treating hormone disorders. This initiative is part of the Advanced Research Projects Agency for Health's (ARPA-H) Resilient Extended Automatic Cell Therapies (REACT) program.
- 12/17/2024
|
Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out
- STONY BROOK, NY / ACCESSWIRE / December 16, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its fourth quarter and fiscal year 2024 financial results after the market close on Tuesday, December 17, 2024. The Company will host a conference call for the investment community to coincide with an update on its GMP manufacturing facility build-out on Thursday, January 9, 2025, at 4:30 p.m.
- 12/16/2024
|
Ferrari has Formula One in its DNA, CEO says after Cadillac supply deal
- Ferrari Chief Executive Benedetto Vigna said Formula One was in the DNA of the company as earlier on Tuesday it announced it would supply engines and gearboxes to a new Cadillac Formula One team in a multi-year agreement from 2026.
- 12/10/2024
|
Ginkgo Bioworks: Unproven Transition But 2025 Is Looking Better
- Ginkgo Bioworks reported solid Q3 results, but underlying performance was weaker than the financials suggest after accounting for meaningless non-cash revenue. Ginkgo's new business model focuses on upfront value creation and solutions which reduce friction in the customer acquisition process. While Ginkgo continues to introduce new tools and is landing customers with these products, it is too early to say whether Ginkgo will succeed as a CRO.
- 11/18/2024
|
Ginkgo Bioworks: Not Enough Progress
- Ginkgo Bioworks reported mixed Q3 results, with a $45 million one-time revenue boost masking underlying revenue growth issues. Despite cost cutting efforts, Ginkgo continues to report large losses, and $325 million of cash was burned in the first nine months of 2023. The balance sheet is weakening, and long-term revenue estimates have continued to move lower.
- 11/13/2024
|
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2024 Earnings Call Transcript
- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q3 2024 Results Conference Call November 12, 2024 5:30 PM ET Company Participants Megan LeDuc - Manager, IR Jason Kelly - Founder, CEO & Director Mark Dmytruk - CFO Conference Call Participants Tejas Savant - Morgan Stanley Matt Sykes - Goldman Sachs John Kim - Bank of America Mark Massaro - BTIG Jacquie Kesa - TD Cowen Megan LeDuc Good evening. I'm Megan LeDuc, Manager of Investor Relations at Ginkgo Bioworks.
- 11/12/2024
|
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q3 Loss, Tops Revenue Estimates
- Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $2.40. This compares to loss of $3.60 per share a year ago.
- 11/12/2024
|
What's happening with 23andMe? Mass layoffs and restructuring are the latest blow for the embattled DNA testing company
- DNA-testing company 23andMe (Nasdaq: ME), once an industry leader that attracted millions of customers, including rapper Snoop Dogg and investor Warren Buffett, has announced significant cuts to its operations, with plans to lay off 200 employees, or roughly 40% of its workforce. The company also said it will discontinue development of its therapeutic programs.
- 11/12/2024
|
Ginkgo Bioworks Reports Third Quarter 2024 Financial Results
- Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions Ginkgo signs new and expanded deals with Novo Nordisk and achieves a major research milestone with Merck BOSTON , Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September 30, 2024. The update, including a webcast slide presentation with additional details on the third quarter and supplemental financial information will be available at investors.ginkgobioworks.com.
- 11/12/2024
|
Ginkgo Bioworks Advances Collaboration with Merck to Improve Biologics Manufacturing
- BOSTON , Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the completion of the first milestone of a previously announced partnership with Merck , known as MSD outside of the United States and Canada, focused on improving biologic manufacturing. As part of this milestone completion, Ginkgo will receive a research milestone payment of $9 million in cash.
- 11/12/2024
|
Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small cell lung cancer,” in JAMA Network Open. Tempus recently conducted a retrospective study of more than 5,500 patients with advanced non-small cell lung cancer (NSCLC) and found that concurrent RNA- and DN.
- 11/11/2024
|
Ginkgo Bioworks Announces Date of Third Quarter 2024 Results Presentation
- Presentation and Q&A session scheduled for post-market on Tuesday, November 12, 2024 BOSTON , Nov. 5, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2024, on Tuesday, November 12, 2024, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.
- 11/05/2024
|
Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market
- Ginkgo Bioworks Holdings, Inc. (DNA) closed at $7.63 in the latest trading session, marking a -1.55% move from the prior day.
- 11/04/2024
|
Applied DNA Announces Pricing of $6.5 Million Registered Direct Offering and Concurrent Private Placement
- STONY BROOK, NY / ACCESSWIRE / October 30, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the pricing of a registered direct offering and concurrent private placement with gross proceeds to the Company expected to be approximately $6.5 million before deducting placement agent fees and other estimated expenses payable by the Company. The offering is comprised of 20,312,500 shares (the "Shares") of the Company's common stock (or pre-funded warrants in lieu thereof) at a purchase price of $0.32 per share of common stock (or pre-funded warrants in lieu thereof, which shall have the same purchase price, less the exercise price of $0.0001) in a registered direct offering priced at-the-market under Nasdaq rules.
- 10/30/2024
|
PacBio Announces SPRQ Chemistry for Revio Sequencing Systems, a Major Advance Reducing the Cost of a HiFi Human Genome to less than $500
- New long-read sequencing chemistry reduces DNA input requirements four-fold, enables a 33% increase in data output per SMRT Cell, improves methylation calling, and expands support for multiomics New long-read sequencing chemistry reduces DNA input requirements four-fold, enables a 33% increase in data output per SMRT Cell, improves methylation calling, and expands support for multiomics
- 10/29/2024
|
DNA & RNA Banking Services Market Report 2024-2030, Featuring EasyDNA, DNA Genotek, 23andMe, GoodCell, ProteoGenex, Infinity Biologix, deCODE genetics, LGC Biosearch Technologies & PreventionGenetics
- Dublin, Oct. 28, 2024 (GLOBE NEWSWIRE) -- The "DNA & RNA Banking Services Market Size, Share and Trends Analysis Report by Service, Specimen (Blood, Buccal Swabs & Hair Follicles, Others), Application, End-use 2024-2030" report has been added to ResearchAndMarkets.com's offering. The global DNA & RNA banking services market size is expected to reach USD 10.92 billion by 2030, registering a CAGR of 5.5% from 2024 to 2030.
- 10/28/2024
|
Modifi Biosciences Acquired by Merck
- Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat cancers Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat cancers
- 10/23/2024
|
Applied DNA to Participate in the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16
- STONY BROOK, NY / ACCESSWIRE / October 15, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA"), a leader in PCR-based DNA technologies, today announced that Dr. James A. Hayward, president and chief executive officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit.
- 10/15/2024
|
Pet DNA Testing Market Report 2024: Industry Analysis and Forecast (2018-2030) with Share & Strategy Insights of Leading Players - Zoetis (Basepaws), Mars Petcare (Wisdom Panel), Orivet Genetic Pet Care & More
- Dublin, Oct. 15, 2024 (GLOBE NEWSWIRE) -- The "Pet DNA Testing Market Size, Share and Trends Analysis 2024-2030" report has been added to ResearchAndMarkets.com's offering. The global pet DNA testing market is expected to reach USD 676.64 million by 2030, registering to grow at a CAGR of 9.45% from 2024 to 2030.
- 10/15/2024
|
KBRA Assigns Preliminary Ratings to Freddie Mac's STACR 2024-DNA3
- NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns preliminary ratings to 24 classes from Freddie Mac Structured Agency Credit Risk (STACR®) REMIC 2024-DNA3 Notes, Freddie Mac STACR REMIC Trust 2024-DNA3 (STACR 2024-DNA3), a credit risk sharing transaction with a total note offering of $642,500,000. STACR 2024-DNA3 features loans with loan-to-value (LTV) ratios greater than 60%, but less than or equal to 80%. The Offered Notes represent obligations of the STACR 2024-DNA3 Trust in a credit-linked note stru.
- 10/03/2024
|
Virica Biotech and Ginkgo Bioworks Announce Partnership to Accelerate AAV Gene Therapy Manufacturing
- BOSTON & OTTAWA, Ontario--(BUSINESS WIRE)-- #AAV--Virica and Ginkgo announce a strategic partnership to enhance the productivity of adeno-associated virus (AAV) gene therapy manufacturing platforms.
- 10/03/2024
|
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Slides as Market Rises: Facts to Know Before You Trade
- Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $7.70, moving -0.77% from the previous trading session.
- 09/26/2024
|
PreAnalytiX, a QIAGEN and BD joint venture, launches novel solution for liquid biopsy from urine samples
- PAXgene Urine Liquid Biopsy Set with collection cup and a nucleic acid stabilizing tube enables non-invasive sample collection and direct cell-free DNA stabilization from urine // QIAGEN to commercialize set with the first verified, standardized and complete preanalytical workflow from urine collection, stabilization and isolation of cell-free DNA // Cell-free DNA in urine can provide important information to data not found in blood samples PAXgene Urine Liquid Biopsy Set with collection cup and a nucleic acid stabilizing tube enables non-invasive sample collection and direct cell-free DNA stabilization from urine // QIAGEN to commercialize set with the first verified, standardized and complete preanalytical workflow from urine collection, stabilization and isolation of cell-free DNA // Cell-free DNA in urine can provide important information to data not found in blood samples
- 09/25/2024
|
Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis
- Innovation Delivers High-Fidelity, Scalable, Non-Toxic On-Premises Biofoundry Capabilities Innovation Delivers High-Fidelity, Scalable, Non-Toxic On-Premises Biofoundry Capabilities
- 09/25/2024
|
NOVUS Leverages Ginkgo Bioworks to Develop Innovative Feed Additives for Animal Agriculture
- BOSTON and CHESTERFIELD, Mo. , Sept. 24, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced its new partnership with NOVUS International, an innovator and leader in intelligent nutrition, to develop advanced feed additives designed to meet the evolving needs of the animal agriculture industry.
- 09/24/2024
|
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement
- STONY BROOK, NY / ACCESSWIRE / September 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that on September 17, 2024, it received a notification letter (the "Notification Letter") from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq"), informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). As previously reported, the Company was notified on July 12, 2024, that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Minimum Bid Price Requirement.
- 09/18/2024
|
Pomerantz LLP Announces that this is a Reminder of a Proposed Class Action Settlement on Behalf of Purchasers of Ginkgo Bioworks Holdings, Inc. Common Stock - DNA
- OAKLAND, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the Northern District of California Oakland Division has approved the following announcement of a proposed class action settlement that would benefit purchasers of Ginkgo Bioworks Holdings, Inc. common stock (NYSE: DNA):
- 09/18/2024
|
Ginkgo Bioworks Launches Ginkgo Datapoints to Transform AI Model Training in Biology
- BOSTON , Sept. 18, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, proudly announces the launch of Ginkgo Datapoints to usher in the next era of biotechnology by making the training of AI models easier and more efficient.
- 09/18/2024
|
Why Ginkgo Bioworks Holdings Stock Raced 9% Higher Today
- The biotech rolled out two new healthtech innovations. One is a large language model (LLM) developed with its partner Alphabet.
- 09/17/2024
|
Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 3rd Annual mRNA Process Development & Manufacturing Summit
- - Co-Hosts Seminar with mRNA CDMO Kudo Bio to Demonstrate Linea IVT Capability for Rapid mRNA Manufacturing - STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced its participation at upcoming mRNA events in Boston this week: 3rd Annual mRNA Process Development & Manufacturing Summit - members of Applied DNA's Biotherapeutics Sales and Business Development teams (collectively 'LineaRx,' a majority-owned Applied DNA company) will attend the 3rd Annual mRNA Process Development & Manufacturing Summit taking place September 17-19, 2024. LineaRx will present its Linea™ IVT platform - a combination of an enzymatically produced DNA template (Linea™ DNA IVT template) coupled with a next-generation RNA polymerase (Linea™ RNAP) - as a solution to enable mRNA producers to manufacture better mRNA faster via simplified workflows and reduced double-stranded RNA (dsRNA) contamination.
- 09/17/2024
|
Applied DNA Receives Linea DNA Follow-on Order from Global Manufacturer of IVDs for Cancer Diagnostic Application
- - Recurring and Accelerated Receipt of Order Reflects Customer Commitment to Linea DNA - STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced it has received a follow-on order valued at more than $500,000 for a quantity of Linea™ DNA from a global manufacturer of in vitro diagnostics (IVDs). The follow-on order was placed under a long-standing supply agreement for the bulk manufacture of Linea DNA (non-therapeutic) used in the manufacture of a cancer diagnostic test.
- 09/17/2024
|
Ginkgo Bioworks Launches New Protein LLM and Model API Built on Google Cloud Technology
- Protein large language model (LLM) designed to help enterprises accelerate drug development coming to Google Cloud's Vertex AI Model Garden soon; one of the first-of-its-kind in the industry Model API programmable interface now available for individual scientists and researchers to quickly test and advance work BOSTON , Sept. 17, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced two new offerings that will make it easier for pharmaceutical and biotech companies to develop new medicines, building on the partnership announced with Google Cloud last year.
- 09/17/2024
|
Rakovina Therapeutics and Variational AI Announce Drug Discovery Collaboration
- Companies will jointly research DNA-damage response kinase targets to identify potential drug candidates for the treatment of cancer Companies will jointly research DNA-damage response kinase targets to identify potential drug candidates for the treatment of cancer
- 09/17/2024
|
Applied DNA Launches Mpox Clade I and Clade II Testing Service
- STONY BROOK, NY / ACCESSWIRE / September 11, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has launched an expansion of its clinical testing services for the detection of Mpox (formerly monkeypox) to include testing for both mpox Clade I and Clade II. The launch of the expanded mpox testing service comes after ADCL's interaction with relevant regulatory bodies, including the New York State Department of Health (NYSDOH) and the U.S. Food and Drug Administration (FDA).
- 09/11/2024
|
Down a Monstrous 90% This Year, Is There Any Hope Left for Ginkgo Bioworks Investors?
- Ginkgo Bioworks hopes to revolutionize many industries with bioengineered products. Its business, however, remains deeply unprofitable.
- 09/05/2024
|
Applied DNA Selected by LRQA for Isotopic Testing Pilot Project in Pakistan
- - Pilot Project To Demonstrate Effectiveness of CertainT® for Cotton Textile Traceability - STONY BROOK, NY / ACCESSWIRE / September 4, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced the receipt of a subcontract award from LRQA following a competitive tender for a pilot isotopic testing program. Under the terms of the subcontract, Applied DNA, together with its traceability partner, Isotech (a Stratum Reservoir company), will employ CertainT® to conduct isotopic testing and analysis to support cotton traceability in Pakistan.
- 09/04/2024
|
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Ginkgo Bioworks Holdings, Inc. Common Stock - DNA
- OAKLAND, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the Northern District of California Oakland Division has approved the following announcement of a proposed class action settlement that would benefit purchasers of Ginkgo Bioworks Holdings, Inc. common stock (NYSE: DNA):
- 09/04/2024
|
2 Big Risks and 2 Big Opportunities for Ginkgo Bioworks Stock
- Ginkgo Bioworks isn't yet profitable, so it's running on a finite amount of cash. Cutting expenses may actually cause the company to lose out on revenue.
- 09/03/2024
|
3 Stocks Hitting New 52-Week Lows. Should You Back Up the Truck?
- Dumpster diving can be a lucrative pastime. One man's trash is another's treasure.
- 09/03/2024
|
This 1 AI Stock Could Revolutionize Biotech and Pharma
- Ginkgo Bioworks seeks to create a high-throughput biopharma services platform. So far, that platform isn't profitable, but it can still generate a lot of scientific data.
- 09/02/2024
|
Ginkgo Bioworks Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference
- BOSTON , Aug. 30, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Chief Financial Officer, Mark Dmytruk, is scheduled to participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, September 6 at 11:30 a.m. ET. Further details, a webcast link, and a replay of the fireside chat will be posted on the company's investor relations website at https://investors.ginkgobioworks.com/events.
- 08/30/2024
|
Maravai LifeSciences' Cygnus & TriLink Unveil AccuRes DNA Kits
- MRVI's Cygnus and TriLink introduce AccuRes kits, setting a new standard in host cell DNA quantification with unmatched sensitivity and specificity.
- 08/29/2024
|
From Promise to Peril: The Downfall of Ginkgo Bioworks
- “Our revenue has grown substantially, and we are proud of the progress we've made in establishing strategic partnerships. The robust pipeline of projects we have in place positions us well for continued financial success.
- 08/26/2024
|
Down 88% in 1 Year, What's Next for Ginkgo Bioworks Stock?
- Ginkgo Bioworks is still not anywhere close to being operationally profitable. Management isn't planning on it becoming profitable anytime soon.
- 08/24/2024
|
Why Is Diagnostic Tests Provider Applied DNA Sciences Stock Trading Higher On Friday?
- Applied DNA Sciences, Inc. APDN stock traded higher on Friday on a strong session volume of 114.23 million, compared to the average volume of 6.78 million, according to data from Benzinga Pro.
- 08/23/2024
|
Applied DNA Submits Validation Package to New York State Department of Health to Expand Linea Mpox Virus 1.0 Assay to Mpox Clade I
- -Validation Studies Confirmed the Assay Can Detect Mpox Clade I and Clade Ib in addition to Clade II- STONY BROOK, NY / ACCESSWIRE / August 23, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (the "Company"), a leader in PCR-based DNA technologies, today announced that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has submitted a validation package to the New York State Department of Health (NYSDOH) in support of an expansion of the permitted use of its Linea™ Mpox Virus 1.0 Assay (the "Assay") to include both mpox clade I and clade II. The Company's validation studies concluded that the Assay's primers and probe have 100% homology to mpox clade I and clade Ib, the latter of which was the subject of the World Health Organization's (WHO) recently declared public health emergency of international concern.
- 08/23/2024
|
Ginkgo Bioworks: Here Comes The Test
- Ginkgo Bioworks has struggled with missed revenue targets, leading to a significant decline in share value. The recent Q2 report showed a 30% decrease in total revenues, with cost structure still a major issue for the company. Balance sheet weakening as cash reserves decrease, putting pressure on working capital and financial flexibility.
- 08/21/2024
|
Applied DNA To Submit Application to New York State Department of Health to Expand Intended Use of Linea Mpox Virus 1.0 Assay to Mpox Clade I
- STONY BROOK, NY / ACCESSWIRE / August 19, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced its intention to seek an expansion of the approved intended use of its Linea™ Mpox Virus 1.0 Assay (the "Assay") to include the detection of mpox Clade I that is the subject of the World Health Organization's (WHO) 14 August 2024 declaration of a public health emergency of international concern (PHEIC). The Company's internally generated data show that the Assay can detect the genetic sequence of mpox Clade I and is now undertaking validation studies to enable the filing of necessary documentation with the New York State Department of Health (NYSDOH).
- 08/19/2024
|
Down 86% This Year, Is Ginkgo Bioworks Stock a Bargain Now?
- Ginkgo Bioworks' market cap has plummeted from more than $25 billion at its peak to less than $600 million at recent prices. The company has announced heaps of layoffs this year in response to heavy losses.
- 08/15/2024
|
Prediction: Artificial Intelligence Will Lead to Higher Returns With Biotech Stocks
- AI holds tremendous promise for the biopharma industry. Using AI to identify candidates for new drugs is already happening.
- 08/13/2024
|
Ginkgo Bioworks Reports Second Quarter 2024 Financial Results
- Ginkgo provides update on its restructuring process including estimated annualized cost savings of over $85 million from reduction in force BOSTON , Aug. 8, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended June 30, 2024. The update, including a webcast slide presentation with additional details on the second quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.
- 08/08/2024
|
Applied DNA Announces Third Quarter Fiscal Year 2024 Financial Results
- - Conference Call/Webcast Scheduled for Today at 4:30 PM ET - STONY BROOK, NY / ACCESSWIRE / August 8, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated financial results for its third fiscal quarter ended June 30, 2024. The Company's Form 10-Q can be viewed at https://investors.adnas.com/sec-filings/.
- 08/08/2024
|
Global Agriculture Biologicals Testing Market Size To Worth USD 5.61 Billion by 2033 | CAGR of 7.20%
- The Global Agriculture Biologicals Testing Market Size was Valued at USD 2.80 Billion in 2023 and the Worldwide Agriculture Biologicals Testing Market Size is Expected to Reach USD 5.61 Billion by 2033, according to a research report published by Spherical Insights & Consulting. Companies covered: ALS Group, Anadiag Group, Bionema Group Limited, BioTecnologie BT, Eurofins APAL Pty Ltd, Eurofins Scientific SE, i2LResearch, Lallemand Inc., LAUS GmbH, R J Hill Laboratories Limited, SGS SA, Staphyt SA, SynTech Research Group, and Others The Global Agriculture Biologicals Testing Market Size was Valued at USD 2.80 Billion in 2023 and the Worldwide Agriculture Biologicals Testing Market Size is Expected to Reach USD 5.61 Billion by 2033, according to a research report published by Spherical Insights & Consulting. Companies covered: ALS Group, Anadiag Group, Bionema Group Limited, BioTecnologie BT, Eurofins APAL Pty Ltd, Eurofins Scientific SE, i2LResearch, Lallemand Inc., LAUS GmbH, R J Hill Laboratories Limited, SGS SA, Staphyt SA, SynTech Research Group, and Others
- 08/08/2024
|
Applied DNA to Report Third Quarter Fiscal 2024 Financial Results on Thursday, August 8, 2024
- STONY BROOK, NY / ACCESSWIRE / August 7, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its third quarter fiscal 2024 financial results after market close on Thursday, August 8, 2024. In conjunction with this announcement, Applied DNA management will host a conference call for analysts and members of the investment community starting at 4:30 p.m.
- 08/07/2024
|
DNA Stock Alert: Ginkgo Bioworks Plunges on Plan for Reverse Stock Split
- Ginkgo Bioworks (NYSE: DNA ) stock is falling on Friday after the cell programming company announced plans for a reverse split of its shares. Ginkgo Bioworks wants to enact a reverse stock split for DNA shares in the range of one-for-20 to one-for-40.
- 08/02/2024
|
Ginkgo Bioworks to Hold Special Meeting of Shareholders
- Special meeting to take place virtually on August 14, 2024 at 4:00 pm ET BOSTON, Aug. 2, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, will be holding a special meeting of shareholders virtually on August 14, 2024 at 4:00 pm ET to vote to permit, at the discretion of the Board of Directors, a reverse stock split of the issued and outstanding shares of Class A common stock and Class B common stock in a range of not less than one-for-twenty (1:20) and not more than one-for-forty (1:40), with the final ratio to be determined by the Board of Directors. Shareholders will also vote to approve Ginkgo's Amended and Restated Certificate of Incorporation, which has been updated to permit officer exculpation and remove provisions related to our merger with Soaring Eagle Acquisition Corp. and our domestication process, which are no longer relevant to our business.
- 08/02/2024
|
Ginkgo Bioworks Announces Date of Second Quarter 2024 Results Presentation
- Presentation and Q&A session scheduled for post-market on Thursday, August 8, 2024 BOSTON , Aug. 1, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the second quarter ended June 30, 2024, on Thursday, August 8, 2024, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.
- 08/01/2024
|
Ginkgo Bioworks Holdings, Inc. (DNA) Advances While Market Declines: Some Information for Investors
- Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $0.37, signifying a +0.3% move from its prior day's close.
- 07/30/2024
|
CORRECTING AND REPLACING: Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Annual mRNA-based Therapeutics Summit
- - This Version Removes the Use of 'Presentation' from the Prior-issued Headline - - Linea™ IVT Platform Delivers All The Benefits of Conventional IVT Without dsRNA Contamination - STONY BROOK, NY / ACCESSWIRE / July 29, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, will present a poster at the 4th Annual mRNA-based Therapeutics Summit taking place July 29 - 31, 2024, in Boston. The poster presents the Company's Linea™ IVT platform - a combination of an enzymatically produced DNA template (Linea™ DNA IVT template) coupled with a next-generation RNA polymerase - as a solution to enable mRNA producers to manufacture better mRNA faster via simplified workflows and reduced double-stranded RNA (dsRNA) contamination.
- 07/29/2024
|
Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Presentation Annual mRNA-based Therapeutics Summit
- - Linea™ IVT Platform Delivers All The Benefits of Conventional IVT Without dsRNA Contamination - STONY BROOK, NY / ACCESSWIRE / July 29, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, will present a poster at the 4th Annual mRNA-based Therapeutics Summit taking place July 29 - 31, 2024, in Boston. The poster presents the Company's Linea™ IVT platform - a combination of an enzymatically produced DNA template (Linea™ DNA IVT template) coupled with a next-generation RNA polymerase - as a solution to enable mRNA producers to manufacture better mRNA faster via simplified workflows and reduced double-stranded RNA (dsRNA) contamination.
- 07/29/2024
|
Applied DNA Enters into Multi-Year Commercialization Agreement with Indus Group for Large-Scale Implementation of CertainT Cotton Traceability
- - Indus Group Consumes Approximately 450 Million Pounds of Cotton Annually for the Manufacture of Apparel, Footwear, and Accessories for Global Brands and Retailers - STONY BROOK, NY / ACCESSWIRE / July 25, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the signing of a five-year license and commercialization agreement for its CertainT ® traceability platform (the "Agreement") with Indus Group ("Indus") a multinational apparel/textile manufacturing and sourcing company with a reputation for cutting-edge fabric technology and product innovation. Indus consumes approximately 450 million pounds of cotton annually.
- 07/25/2024
|
Why the Market Dipped But Ginkgo Bioworks Holdings, Inc. (DNA) Gained Today
- The latest trading day saw Ginkgo Bioworks Holdings, Inc. (DNA) settling at $0.30, representing a +0.6% change from its previous close.
- 07/24/2024
|
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA)
- NEW YORK , July 23, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) on behalf of the company's shareholders. The investigation seeks to determine whether Ginkgo's directors breached their fiduciary duties in connection with recent corporate actions.
- 07/23/2024
|
7 Meme Mania Stocks: Which Are FOMO and Which Are Free Money?
- Meme stocks, fueled by social media hype, can soar or crash rapidly. While some see potential for explosive gains, others pose a high risk.
- 07/23/2024
|
U.S. Defense Logistics Agency Exercises 1-Year Option Period in Applied DNA Counterfeit Mitigation Contract
- STONY BROOK, NY / ACCESSWIRE / July 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that the U.S. Defense Logistics Agency (DLA) exercised the first one-year option period of a three-year base contract with two one-year option periods entered into in May 2021. The contract supports DLA's counterfeit mitigation initiatives and product verification and testing programs specific to FSC 5962 microcircuits.
- 07/18/2024
|
AI Demand and New Deals Make Ginkgo Bioworks Stock a Speculative Buy
- Ginkgo Bioworks Holdings (NYSE: DNA ), which develops platforms for cell programming, has multiple, positive potential catalysts and a rather low valuation. Moreover, the shares should benefit from investors' recent interest in buying small-cap stocks that have lost a great deal of their value.
- 07/18/2024
|
DNA Stock: Ginkgo Bioworks Announces New Collaboration
- Biotechnology specialist Ginkgo Bioworks (NYSE: DNA ) is seeing shares skyrocket today following an announcement of a potentially lucrative collaboration. Specifically, Ginkgo will partner with Syngenta, which is billed as a “leader in agricultural innovation.
- 07/16/2024
|
Syngenta collaborates with Ginkgo Bioworks to enable faster launch of innovative biologicals
- Syngenta will leverage Ginkgo's Ag Biologicals capabilities to optimize secondary metabolite production for a pioneering biological solution BASEL, Switzerland and BOSTON , July 16, 2024 /PRNewswire/ -- Syngenta Crop Protection, a leader in agricultural innovation, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new collaboration aimed at accelerating the launch of a new biological solution. The two companies have previously collaborated on next-generation seed technology.
- 07/16/2024
|
Down 81% in 2024, Is Ginkgo Bioworks Stock Still a Buy?
- Ginkgo Bioworks is scaling down its workforce and operating footprint. It's also aiming to restrict the scope of the services it offers.
- 07/14/2024
|
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
- The latest trading day saw Ginkgo Bioworks Holdings, Inc. (DNA) settling at $0.32, representing a -1.51% change from its previous close.
- 07/11/2024
|
3 Stocks to Avoid Like the Plague in 2024
- It's crucial to steer clear of potential pitfalls that could sink your portfolio. With the S&P 500 and Nasdaq posting impressive year-to-date gains, it's tempting to get caught up in the bullish fervor.
- 07/11/2024
|
3 High-Risk, Sky-High Reward Stocks to Buy for Under $1
- High-risk penny stocks are known for their volatility. They often feature low trading volumes, minimal prices and unstable financial and fundamental standings.
- 07/10/2024
|
Stay Away: Why Ginkgo Bioworks Stock Is Not for the Faint-Hearted
- There's definitely a science to picking beaten-down gems in the stock market. If you get it wrong, you could lose a lot of money.
- 07/10/2024
|
3 Biotech Stocks to Sell in July Before They Crash & Burn
- The biotech segment is a relatively new sector that combines the fields of biology and technology. It integrates natural sciences from biology and engineering aspects from technology to develop products with meaningful applications in areas like medicine, agriculture, therapeutics, and more.
- 07/05/2024
|
3 Biotech Stocks Turning DNA Dreams Into Dollars
- When discussing biotechnology, many focus on medication based on biochemical compounds and their downstream effects. Yet several branches of medical genetics and therapeutics have begun to find novel ways to treat and prevent diseases through gene editing, protein manipulation and overall DNA repair.
- 07/05/2024
|
3 Top-Rated Gene Editing Stocks Actually Making Money
- Gene editing utilizes enzymes that cut part of the DNA strand, allowing the insertion of replacement DNA. Several approaches to gene editing have been developed, the most well-known of which is CRISPR-Cas9.
- 07/03/2024
|
Rags to Riches: 3 Biotech Stocks That Could Make Early Investors Rich
- In 2024, the iShares Biotechnology ETF (NASDAQ: IBB ) is up just over 1.5%. If you're looking for steady, dividend-paying stocks, you can find a number of biotech stocks to buy from the holdings in this fund.
- 06/27/2024
|
Ginkgo Bioworks Layoffs Expand to 400 Job Cuts
- Ginkgo Bioworks (NYSE: DNA ) layoffs continue today with the cell programming company announcing additional job cuts. The latest update to the Ginkgo Bioworks layoffs reveals that the company is planning to cut at least 35% of its workers.
- 06/26/2024
|
Why Ginkgo Bioworks Stock Is Sinking Today
- Ginkgo Bioworks continued its slide from earlier in the week. The company is cutting 25% of its workforce.
- 06/26/2024
|
Ginkgo Bioworks Layoffs 2024: What to Know About the Latest DNA Job Cuts
- Ginkgo Bioworks (NYSE: DNA ) layoffs are coming for 158 of the company's employees and more are on the way. Ginkgo Bioworks has revealed that it's going to be cutting 158 jobs as part of its effort to reduce its labor costs by 25%.
- 06/24/2024
|
Integrated DNA Technologies Introduces New HIV Panel to Advance Virology Research
- CORALVILLE, Iowa--(BUSINESS WIRE)-- #Amplicon--Advancing virology research: IDT's xGen™ HIV Amplicon Panel consisting of primers designed to cover 99.3% of the HIV genome is now available.
- 06/24/2024
|
5-Year Fortune Forecast: 3 Penny Stocks Destined for Massive Gains
- Investing in penny stocks can reward bold, patient investors. But patience can be in short supply when you can just buy NVIDIA (NASDAQ: NVDA ) and sleep well at night.
- 06/20/2024
|
Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics
- - Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability - - Applied DNA Secures Commercial Linea RNAP Quantity Sufficient to Support Anticipated Near-Term Demand - STONY BROOK, NY AND JUPITER, FL / ACCESSWIRE / June 20, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, and Alphazyme LLC (Alphazyme), a Maravai LifeSciences company (NASDAQ:MRVI) and global provider of specialty enzymes used in the life sciences sector, announced the successful conclusion of the companies' previously announced Linea™ RNAP manufacturing scale-up agreement. The joint process development project resulted in an over 70% reduction in Linea RNAP manufacturing costs and the manufacture of a quantity of Linea RNAP sufficient to support Applied DNA's anticipated near-term demand for critical starting material for mRNA production.
- 06/20/2024
|
7 Penny Stocks to Sell in June Before They Crash & Burn
- The stock market continues to climb. But in this case, a rising tide isn't necessarily lifting all boats.
- 06/19/2024
|
Applied DNA Partners with GenXys Health Care Systems to Deploy Clinical Decision Support System for Pharmacogenetic (PGx) Testing
- Partnership Will Aid Physicians in Precision Prescribing Decisions Based on Applied DNA's TR8™ Pharmacogenomic (PGx) Test STONY BROOK, NY / ACCESSWIRE / June 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a global leader in PCR-based DNA technologies, today announced that its molecular diagnostics subsidiary, Applied DNA Clinical Labs, LLC (ADCL), will utilize the GenXys Health Care Systems (GenXys) suite of clinical decision support software for interpretation and reporting of ADCL's New York State Department of Health-approved TR8™ pharmacogenomic (TR8 PGx) test. The partnership is designed to improve patient outcomes and reduce healthcare costs through a data-driven approach that relates an individual's genetic factors to potential responses to prescription drugs.
- 06/18/2024
|
Charles River and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy
- WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany, today announced a plasmid DNA and retrovirus vector production program agreement. As part of Charles River's Cell and Gene Therapy (CGT) Accelerator Program (CAP), Captain T Cell will have access to established plasmid and viral vector contract development and manufacturing organization (CDMO) capabilities and advisor.
- 06/17/2024
|
Applied DNA Receives Approval for TR8(TM) Pharmacogenomic (PGx) Testing Service from New York State Department of Health
- STONY BROOK, NY / ACCESSWIRE / June 13, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that the New York State Department of Health ("NYSDOH") approved the Company's TR8™ PGx ("TR8") pharmacogenomic (PGx) testing service. The Company is currently in discussions to provide large-scale testing to enterprise customers, healthcare networks, and concierge physicians seeking to add PGx testing to their test menu.
- 06/13/2024
|
QIAGEN launches new QIAcuity digital PCR assays for microbial applications, enhancing infectious disease research and surveillance
- 35 new wet-lab tested digital PCR Microbial DNA Detection Assays on research platform GeneGlobe target a wide range of pathogens causing tropical diseases, sexually transmitted and urine tract infections // QIAcuity digital PCR technology enables precise and sensitive detection of pathogens, supporting infectious disease research and public health efforts // New assays add to QIAGEN's comprehensive portfolio for microbial research showcased at ASM Microbe conference from June 13-17 35 new wet-lab tested digital PCR Microbial DNA Detection Assays on research platform GeneGlobe target a wide range of pathogens causing tropical diseases, sexually transmitted and urine tract infections // QIAcuity digital PCR technology enables precise and sensitive detection of pathogens, supporting infectious disease research and public health efforts // New assays add to QIAGEN's comprehensive portfolio for microbial research showcased at ASM Microbe conference from June 13-17
- 06/11/2024
|
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
- The S&P 500 has hit more than one record high this year, and technology stocks have led the gains. It's a great idea to get in on stocks that have remained in the doldrums but could have a bright future.
- 06/11/2024
|
Integrated DNA Technologies Announces New Primers and Probe Set to Identify H5N1 Avian Influenza
- CORALVILLE, Iowa--(BUSINESS WIRE)-- #AvianFlu--A new PCR/qPCR solution from IDT will support surveillance and monitoring of the current H5N1 strain of bird flu.
- 06/10/2024
|
After Plunging -40.22% in 4 Weeks, Here's Why the Trend Might Reverse for Ginkgo Bioworks (DNA)
- Ginkgo Bioworks (DNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 06/07/2024
|
Applied DNA Announces Notice of Allowance for U.S. Patent Covering Fundamental Aspect of its Linea(TM) IVT Platform
- Patent covers the Composition of the Company's Proprietary Linea™ RNAP, a Core Technology Empowering the Linea™ IVT Platform Patent Application Also Currently Pending in Key International Markets STONY BROOK, NY / ACCESSWIRE / June 5, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, announced today that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application 18/302,247, entitled "Compositions and Methods for RNA Synthesis." The resulting patent will cover the composition of the Company's chemically modified RNA polymerase enzyme branded Linea™ RNAP, with expected patent protection into 2041.
- 06/05/2024
|
Merck's Innovative Oncology Pipeline of DNA Damage Response Inhibitors and Antibody-Drug Conjugates Poised to Advance Cancer Treatment
- DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today shared updates on the company's oncology pipeline and focused approach to the research and development of potential new medicines designed to improve the futures of people with cancer. This year, the company plans to open multiple new Phase Ib and II clinical studies for tuvusertib and M9466, key assets from its broad portfolio of DNA damage response (DDR) inhibitors; has advanced its lead antibody-drug.
- 06/03/2024
|
3 Sorry Biotech Stocks to Sell in May While You Still Can
- Morgan Stanley recently released its bullish take on the biotech space, driven by anticipated interest rate cuts and a surge in mergers and acquisitions (M&A) activity. The analyst firm states biotech stocks typically outshine the market just before a rate cut.
- 05/31/2024
|
Ginkgo Bioworks Stock: Bull vs. Bear
- Ginkgo is embarking on a cost-cutting plan that could pave the path to profitability and share performance. The main bear case against Ginkgo is there's no compelling reason to buy the stock right now.
- 05/31/2024
|
Should You Buy the Dip on Ginkgo Bioworks Stock?
- Ginkgo Bioworks is still struggling with operating efficiency. Management is signaling that its processes may be streamlined.
- 05/30/2024
|
QIAGEN launches new library preparation kit, facilitating multiomic studies and advancing precision medicine
- QIAseq Multimodal DNA/RNA Lib Kit enables streamlined DNA and RNA library preparation for next-generation sequencing from a single sample // New kit advances precision medicine by facilitating multiomic studies and Comprehensive Genomic Profiling, crucial for understanding complex diseases like cancer // Researchers are provided with the first multimodal sequencing kit for multiple sample types, offering high flexibility and sensitivity, saving sample material and time QIAseq Multimodal DNA/RNA Lib Kit enables streamlined DNA and RNA library preparation for next-generation sequencing from a single sample // New kit advances precision medicine by facilitating multiomic studies and Comprehensive Genomic Profiling, crucial for understanding complex diseases like cancer // Researchers are provided with the first multimodal sequencing kit for multiple sample types, offering high flexibility and sensitivity, saving sample material and time
- 05/29/2024
|
2 Cathie Wood Biotech Stocks That Could Be Worth the Risk
- Cathie Wood likes to invest in risky biotech stocks. Ginkgo Bioworks has ambitions to disrupt biopharma manufacturing.
- 05/29/2024
|
Integrated DNA Technologies Invests in New U.S. Synthetic Biology Manufacturing Facility
- CORALVILLE, Iowa--(BUSINESS WIRE)-- #AdvancesinSyntheticBiology--IDT's newly expanded U.S. manufacturing site provides a growth runway for manufacturing of synthetic biology products to support growing demand.
- 05/28/2024
|
3 Things You Need to Know if You Buy Ginkgo Bioworks Today
- Ginkgo Bioworks is using a unique approach to laboratory automation. It's also spending a lot of its finite supply of money on this endeavor.
- 05/25/2024
|
Down 72%. Is Ginkgo Bioworks a Buy on the Dip?
- Shares of Ginkgo Bioworks have been beaten severely in response to heavy financial losses. The company's cell foundry could disrupt the biopharmaceutical manufacturing industry.
- 05/25/2024
|
Ginkgo Bioworks Stock Has 37.5% Downside, According to 1 Wall Street Analyst
- Ginkgo Bioworks (NYSE: DNA) stock has dropped more than 10% since its latest quarterly report showing a more than 53% decline in Q1 revenue and continued net losses from its business. BTIG analyst Mark Massaro downgraded Ginkgo stock to sell, and lowered his price on this biotech penny stock to just $0.50. It closed Friday at $0.80, so that would be a 37.5% drop. Why rate Ginkgo stock a sell? Where shall I begin? Massaro is most concerned with management commentary that new "cell programs" -- of which the company expects to add 100 this year -- are no longer a great forecaster of revenue growth, and may give investors a false impression of the company's revenue growth rate. The analyst wrote that it will be "difficult to model how new cell program adds will flow into revenue growth in 2024, 2025, and beyond." For that reason, as well as a change in business plan to offering "lab data as a service," Massaro feels it's safest to avoid the stock for now. I agree. Ginkgo cut costs significantly in the quarter, but largely through cuts in head count and research and development -- troubling moves in a supposed growth stock. Adding to its troubles, the company received a warning from the NYSE that it's at risk of being delisting if the stock price does not rise soon. That's often a precursor to a company announcing a reverse stock split -- yet another no-no for growth stocks. Although possessing enough cash to keep it going for about two years at its current burn rate, I'm just not sure this company is going anywhere fast. To me, that makes Ginkgo stock a sell. Before you buy stock in Ginkgo Bioworks, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Ginkgo Bioworks wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $566,624!* Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*. See the 10 stocks » *Stock Advisor returns as of May 13, 2024 Rich Smith has no position in any of the stocks mentioned. The Motley Fool recommends Roche Ag. The Motley Fool has a disclosure policy. Ginkgo Bioworks Stock Has 37.5% Downside, According to 1 Wall Street Analyst was originally published by The Motley Fool
- 05/20/2024
|
Investment Advisor Says 'Throwing Random Darts At Tickers' Would Beat ARKK As Cathie Wood's Flagship Fund Lags Far Behind Soaring Market: 'How Do They Do It?!'
- Ark Investment Management, led by star investor Cathie Wood, is facing a harsh reality in 2024. While the broader market is hitting record highs, Ark’s actively managed funds are lagging far behind, raising concerns about their future viability. One investment advisor has sounded a stark warning, suggesting Ark’s funds could even go under. What Happened: Ram Ahluwalia of Lumida Wealth pointed to Ark’s flagship ETF, Ark Innovation ETF ARKK, which is currently trading over 70% below its all-time high, a stark contrast to the S&P 500’s recent record highs. ARKK had its heydays amid the recent pandemic as a significant share of its holdings were COVID-19 plays, which capitalized on lockdown restrictions and the work-from-home environment that prevailed at that time. The ETF peaked at $159.70 in mid-February 2021. Source: Benzinga Here are the year-to-performances of Ark’s key ETFs vs the broader market: See Also: Best ETFs To Buy Right Now What Ails Ark Funds? Ahluwalia attributed Ark’s woes to a combination of missed bets and an over-reliance on “vision” over fundamentals. He criticized Ark for selling Nvidia Corp. NVDA stock early in the AI boom and pouring resources into companies like Ginkgo Bioworks Holdings, Inc. DNA and SoFi Technologies, Inc. SOFI. “They sold Nvidia, bought Tesla (We did the opposite). They bought Ginko Biosciences (Never touched it),” he wrote. “They bought $SOFI (We shorted it).” He argued that Ark prioritizes chasing “future ideas” without proper evaluation of traction, valuation, and management credibility. This focus on disruptive innovation, a cornerstone of Ark’s strategy, seems to be backfiring in the current market. While Wood emphasizes long-term growth potential in areas like AI and robotics, many of Ark’s top holdings, including Tesla, Inc. TSLA, haven’t delivered the returns the firm anticipated. “The consistency & statistical significance of how consistently ARKK under-performs is truly incredible,” Ahluwalia said. “If someone asked me to design a product with that kind of performance profile, I don’t think I could do it.” “Literally throwing random darts at tickers would out-perform ARKK,” he added. “How do they do it!?” “Investing the assets of others is a special duty. The lives of others and their family goals are directly impacted,” Ahluwalia said. “Institutions that are chronic destroyers of wealth should absolutely be called out. Most people lack the skill to discern good from bad investing.” Different View: Morningstar strategist Robby Greengold offered another perspective on Ark’s struggles. He suggested the firm lacks the forecasting talent needed for its focus on unproven companies and criticizes the high portfolio correlation due to its thematic investment approach. He argued Ark’s portfolio essentially resembles a tech-heavy fund, despite its focus on disruptive innovation. Why It Matters: Wood’s Ark Invest reigned supreme in early 2021, managing a hefty $59 billion across its ETFs. Today, however, that figure has shrunk by 80% to a mere $11.1 billion, likely a consequence of rising interest rates dampening investor enthusiasm for Wood’s long-term tech bets. In Monday’s premarket session on Monday, ARKK rose 0.33% to $45.60, according to Benzinga Pro data.
- 05/20/2024
|
National Bank of Canada FI Has $51,000 Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
- National Bank of Canada FI raised its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Free Report) by 142.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,672 shares of the company’s stock after buying an additional 18,000 shares during the quarter. National Bank of Canada FI’s holdings in Ginkgo Bioworks were worth $51,000 at the end of the most recent reporting period. Several other large investors have also recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC grew its stake in shares of Ginkgo Bioworks by 52.4% in the third quarter. Commonwealth Equity Services LLC now owns 369,061 shares of the company’s stock valued at $668,000 after acquiring an additional 126,924 shares in the last quarter. Raymond James & Associates grew its position in shares of Ginkgo Bioworks by 4.6% during the 3rd quarter. Raymond James & Associates now owns 193,589 shares of the company’s stock worth $350,000 after purchasing an additional 8,455 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its holdings in shares of Ginkgo Bioworks by 68.5% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 123,923 shares of the company’s stock worth $224,000 after purchasing an additional 50,374 shares during the period. Bank of New York Mellon Corp raised its position in shares of Ginkgo Bioworks by 2.9% in the third quarter. Bank of New York Mellon Corp now owns 4,165,325 shares of the company’s stock valued at $7,539,000 after buying an additional 117,893 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Ginkgo Bioworks by 36.9% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 184,761 shares of the company’s stock valued at $334,000 after buying an additional 49,827 shares during the period. Institutional investors own 78.63% of the company’s stock. Analyst Upgrades and Downgrades Several research firms have recently issued reports on DNA. TD Cowen reduced their target price on Ginkgo Bioworks from $7.00 to $3.00 and set an “outperform” rating on the stock in a report on Friday, March 1st. William Blair downgraded shares of Ginkgo Bioworks from a “market perform” rating to an “underperform” rating in a research note on Friday, May 10th. Morgan Stanley dropped their target price on shares of Ginkgo Bioworks from $2.00 to $1.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 15th. BTIG Research lowered shares of Ginkgo Bioworks from a “neutral” rating to a “sell” rating in a research report on Wednesday, May 15th. Finally, The Goldman Sachs Group lowered their price objective on shares of Ginkgo Bioworks from $1.25 to $1.10 and set a “sell” rating for the company in a research report on Monday, January 22nd. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, Ginkgo Bioworks has an average rating of “Hold” and an average price target of $1.90. View Our Latest Research Report on DNA Ginkgo Bioworks Trading Down 4.0 % Shares of Ginkgo Bioworks stock opened at $0.81 on Monday. The firm’s 50 day moving average is $0.99 and its 200 day moving average is $1.27. The firm has a market capitalization of $1.73 billion, a PE ratio of -1.83 and a beta of 1.42. Ginkgo Bioworks Holdings, Inc. has a 1 year low of $0.72 and a 1 year high of $2.55. Ginkgo Bioworks (NYSE:DNA – Get Free Report) last posted its earnings results on Thursday, May 9th. The company reported ($0.08) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.08). Ginkgo Bioworks had a negative net margin of 409.11% and a negative return on equity of 56.09%. The firm had revenue of $37.94 million for the quarter, compared to analysts’ expectations of $45.50 million. During the same quarter in the previous year, the firm posted ($0.08) earnings per share. As a group, research analysts anticipate that Ginkgo Bioworks Holdings, Inc. will post -0.3 earnings per share for the current year. Insiders Place Their Bets In other news, insider Mark E. Dmytruk sold 47,806 shares of the business’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $0.84, for a total transaction of $40,157.04. Following the sale, the insider now directly owns 925,400 shares in the company, valued at $777,336. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Ginkgo Bioworks news, Director Harry Sloan purchased 297,619 shares of the business’s stock in a transaction dated Tuesday, May 14th. The shares were bought at an average price of $0.91 per share, for a total transaction of $270,833.29. Following the completion of the acquisition, the director now owns 718,540 shares in the company, valued at $653,871.40. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mark E. Dmytruk sold 47,806 shares of the stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $0.84, for a total value of $40,157.04. Following the completion of the sale, the insider now owns 925,400 shares of the company’s stock, valued at $777,336. The disclosure for this sale can be found here. Insiders own 15.05% of the company’s stock. Ginkgo Bioworks Company Profile (Free Report) Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
- 05/20/2024
|
Helical Fusion und das National Institute for Fusion Science gründen eine „HF Collaboration Research Group“ und einen speziellen Experimentierraum für den baldigen kommerziellen Einsatz von Fusionsreaktoren
- TOKYO--(BUSINESS WIRE)--Helical Fusion hat im März 2024 eine Partnerschaftsvereinbarung mit dem National Institute for Fusion Science (NIFS) geschlossen. Das NIFS hat die „HF Collaboration Research Group“ gegründet, deren Aktivitäten im April beginnen. Vor Ort am NIFS wurde für Helical Fusion bereits ein spezieller experimenteller Forschungsraum eingerichtet, der die weltweit größte Versuchsanlage für Supraleiter und Fusion beherbergt. Mit der Unterstützung des NIFS wird Helical Fusion die Realisierung des weltweit ersten kommerziellen Fusionsreaktors beschleunigen. [Hintergrund] Vor dem Hintergrund eines prognostizierten Anstiegs der Weltbevölkerung um ca. 1,7 Milliarden bis 2050* und des damit verbundenen Anstiegs des weltweiten Strombedarfs wird erwartet, dass konventionelle Energieerzeugungsmethoden allein Schwierigkeiten haben werden, diesen Bedarf zu decken. Fusionsenergie bietet eine saubere und sichere Alternative, indem sie unerschöpfliche Brennstoffvorräte wie Meerwasser nutzt, und verspricht daher, eine Technologie zu werden, die in der Lage ist, diese globalen Herausforderungen grundlegend zu bewältigen. Da Japans Energie-Selbstversorgungsgrad einen Tiefstand von 13,3 % erlebt und die Abhängigkeit von fossilen Brennstoffen immer noch über 80 %** liegt, sind Forschungs- und Entwicklungsbemühungen im Gange, um künftige Energiequellen für die Grundlast zu sichern. Das NIFS verfügt über eine der weltweit größten Anlagen für Fusionsexperimente, das Large Helical Device (LHD) in der japanischen Präfektur Gifu. Seit seiner Gründung durch die Regierung im Jahr 1989 steht es an der Spitze der Forschung zu Fusionsreaktoren vom Helix-Typ und hat bemerkenswerte Ergebnisse auf globalem Niveau geliefert. Auf Grundlage der Expertise von NIFS wurde im Jahr 2021 Helical Fusion gegründet und hat die für Startups typische Geschwindigkeit und Agilität genutzt, um die Entwicklung des weltweit ersten kommerziellen Fusionsreaktors für Dauerbetrieb voranzutreiben. Während einzelne gemeinsame Forschungsbemühungen mit dem NIFS im Gange sind, stellen die künftige feste Gründung der „HF Collaboration Research Group“ und die Bereitstellung spezieller Räumlichkeiten für Experimente einen bedeutenden Schritt zur Stärkung der Zusammenarbeit dar, deren Ziel in der baldigen gesellschaftlichen Umsetzung der Fusionsenergie besteht. Referenz: für die Pressemitteilung des National Institute for Fusion Science klicken Sie hier. [Kommentar von Herrn Takaya TAGUCHI (Mitbegründer, CEO von Helical Fusion)] Helical Fusion ist ein Startup, das aus der Fülle hervorragender Forschungsleistungen und dem Fachwissen hervorgegangen ist, das das NIFS im Laufe von mehr als 30 Jahren gesammelt hat. Wir haben zahlreiche gemeinsame Forschungsprojekte mit dem NIFS in Bereichen wie Hochtemperatur-Supraleiter-Magnete und Flüssigmetall-Blankets durchgeführt. Angesichts der wachsenden weltweiten Erwartungen an die Helix-Stellarator-Fusion, als kommerzieller Reaktor im Dauerbetrieb zu arbeiten, haben wir unsere Zusammenarbeit weiter gestärkt, um die Entwicklung durch die Einrichtung dieser Abteilung und spezieller experimenteller Forschungsräume zu beschleunigen. Dies wird nicht nur die gemeinsame Forschung beschleunigen, sondern auch den Fortschritt in unserer firmeneigenen Technologieentwicklung voranbringen, insbesondere im Bereich der Hochtemperatur-Supraleiter-Magnete. Wir drücken dem NIFS-Team unsere Wertschätzung für die Zusammenarbeit aus und sind bestrebt, die Erwartungen aller zu erfüllen, indem wir unsere Bemühungen in Forschung und Entwicklung vorantreiben, um die Entwicklung im globalen Wettbewerb hin zu einem betriebsbereiten, Dauerleistungs-Fusionsreaktor voranzutreiben. Darüber hinaus möchten wir zur Schaffung von Industrien beitragen, in denen Japans führende Technologien, von der Grundlagenforschung bis zur High-End-Fertigung, genutzt werden können. [Kommentar von Herrn Ryo Yasuhara (Leiter der Koordinierungsabteilung Industrie-Akademie-Regierung, NIFS)] Das National Institute for Fusion Science hat mit Helical Fusion eine gemeinsame Forschungsabteilung namens „HF Collaboration Research Group“ eingerichtet, um Forschung und Entwicklung für die praktische Umsetzung von Helix-Fusionsreaktoren durchzuführen. Diese gemeinsame Forschungsgruppe wird hauptsächlich das Fachwissen und die Ressourcen von Helical Fusion und NIFS einbringen, um Forschungsaktivitäten durchzuführen, die auf die Realisierung eines Fusionsreaktors vom Helixtyp abzielen. Ziel des NIFS ist es, durch Forschungsaktivitäten auf höchstem globalen Niveau zur Weiterentwicklung der Fusionswissenschaft und zur Schaffung einer breiten Grundlage für Wissenschaft und Technologie beizutragen. Wir hoffen, dass die in dieser Forschungsgruppe erzielten Erfolge ein Schritt zur Verwirklichung nachhaltiger Energie sein werden. *„World Energy Outlook 2023“ International Energy Agency ( https://www.iea.org/reports/world-energy-outlook-2023 ) **„The white paper on energy usage 2022“, Agency for Natural Resources and Energy ( https://www.enecho.meti.go.jp/about/whitepaper/2023/pdf/ ) [Über uns] Helical Fusion ist ein japanisches Start-up-Unternehmen, das die gesellschaftliche Implementierung von Fusionsenergie durch Fusionsreaktoren mit magnetischem Einschluss zum Ziel hat. In den letzten 60 Jahren wurden über die Welt verteilt verschiedene Fusionsverfahren als Energiequelle der nächsten Generation entwickelt. In Japan wurde die Methode der Helixfusion, bei der eine supraleitende Helixspule mit einer DNA-ähnlichen Doppelhelix zum stabilen Einschließen von Hochtemperaturplasma verwendet wird, intensiv entwickelt und gefördert. Unser Ziel ist es, den weltweit ersten Dauerleistungs-Fusionsreaktor zu entwickeln, indem wir fortschrittlichere Technologien in den Fusionsreaktor vom Typ „Helix-Stellarator“ integrieren. Darüber hinaus haben die firmeneigenen Entwicklungsprojekte von Helical Fusion, einschließlich des Hochtemperatur-Supraleiter-Magneten, der für die Realisierung kommerzieller Reaktoren von entscheidender Bedeutung ist, japanische SBIR-Zuschüsse erhalten, was den Fortschritt auf dem Weg zur Kommerzialisierung weiter beschleunigt. Die Ausgangssprache, in der der Originaltext veröffentlicht wird, ist die offizielle und autorisierte Version. Übersetzungen werden zur besseren Verständigung mitgeliefert. Nur die Sprachversion, die im Original veröffentlicht wurde, ist rechtsgültig. Gleichen Sie deshalb Übersetzungen mit der originalen Sprachversion der Veröffentlichung ab.
- 05/20/2024
|
Q2 2024 Earnings Estimate for Precision BioSciences, Inc. (NASDAQ:DTIL) Issued By HC Wainwright
- Precision BioSciences, Inc. (NASDAQ:DTIL – Free Report) – Research analysts at HC Wainwright raised their Q2 2024 earnings estimates for shares of Precision BioSciences in a note issued to investors on Wednesday, May 15th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.77) for the quarter, up from their prior estimate of ($1.26). HC Wainwright currently has a “Buy” rating and a $60.00 price target on the stock. HC Wainwright also issued estimates for Precision BioSciences’ Q3 2024 earnings at ($0.79) EPS, Q4 2024 earnings at ($0.43) EPS, Q1 2025 earnings at ($0.39) EPS, Q2 2025 earnings at ($0.07) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.26) EPS and FY2025 earnings at ($1.06) EPS. Precision BioSciences (NASDAQ:DTIL – Get Free Report) last announced its quarterly earnings data on Wednesday, March 27th. The company reported ($3.35) earnings per share (EPS) for the quarter, missing the consensus estimate of $3.00 by ($6.35). The firm had revenue of $7.04 million during the quarter, compared to the consensus estimate of $28.50 million. Precision BioSciences had a negative return on equity of 131.69% and a negative net margin of 48.10%. Separately, Guggenheim assumed coverage on shares of Precision BioSciences in a research note on Tuesday, April 30th. They set a “buy” rating and a $19.00 price target for the company. Read Our Latest Report on DTIL Precision BioSciences Price Performance Shares of NASDAQ DTIL opened at $12.40 on Monday. The company has a market cap of $85.93 million, a P/E ratio of -1.66 and a beta of 1.62. Precision BioSciences has a 1 year low of $8.25 and a 1 year high of $27.02. The firm has a 50-day simple moving average of $11.96 and a two-hundred day simple moving average of $11.98. Institutional Trading of Precision BioSciences A number of institutional investors and hedge funds have recently modified their holdings of DTIL. Curi Wealth Management LLC increased its stake in shares of Precision BioSciences by 42.0% during the third quarter. Curi Wealth Management LLC now owns 339,801 shares of the company’s stock worth $116,000 after purchasing an additional 100,530 shares in the last quarter. Tejara Capital Ltd increased its stake in shares of Precision BioSciences by 100.7% during the third quarter. Tejara Capital Ltd now owns 398,614 shares of the company’s stock worth $136,000 after purchasing an additional 200,000 shares in the last quarter. Acadian Asset Management LLC increased its stake in shares of Precision BioSciences by 8.3% during the third quarter. Acadian Asset Management LLC now owns 3,148,243 shares of the company’s stock worth $1,073,000 after purchasing an additional 242,425 shares in the last quarter. Finally, Janus Henderson Group PLC purchased a new stake in shares of Precision BioSciences during the first quarter worth about $7,739,000. Hedge funds and other institutional investors own 37.99% of the company’s stock. Precision BioSciences Company Profile (Get Free Report) Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. See Also Five stocks we like better than Precision BioSciences Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time MarketBeat Week in Review – 5/13 – 5/17 Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed Take-Two Interactive Software Offers 2nd Chance for Investors The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
- 05/20/2024
|
Is Ginkgo Bioworks Holdings Stock a Buy?
- Ginkgo Bioworks has been focusing on developing its artificial intelligence capabilities to enhance its cell programming platform. The company's results, however, have been underwhelming, with sales falling by more than 50% last quarter.
- 05/18/2024
|
4 Small-Cap Value Stocks That Could Go Parabolic
- Small-cap stocks have historically responded positively to interest-rate cuts. These four small-cap equities may be poised for a bull run once the Fed eventually slashes rates.
- 05/16/2024
|
What's the Difference Between Biotech Stocks and TechBio Stocks?
- Some high-tech biotechs claim to be "TechBio" companies. The term signals the use of an automation-heavy approach to biotech.
- 05/15/2024
|
Ginkgo Bioworks to Participate in Two Conferences in May
- BOSTON , May 15, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that management will be participating in two investor conferences in May. TD Cowen's 2nd Annual Sustainability Week: Ginkgo's Senior Director of Policy and Partnerships, Ryan Morhard, will participate in the virtual Sustainable API Manufacturing panel at 4:25 pm ET on May 22, 2024.
- 05/15/2024
|
Sojitz Corporation and Ginkgo Bioworks Announce Plans to Use Synthetic Biology R&D Services to Accelerate Sustainable Manufacturing in Japan
- Sojitz intends to use its extensive network to help Ginkgo foster business connections within the Japanese bioeconomy TOKYO and BOSTON , May 14, 2024 /PRNewswire/ -- Sojitz, a large Japanese general trading company with extensive networks within the Japanese bioeconomy, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that they have entered into a binding definitive agreement. Together, Sojitz and Ginkgo aim to build connections with key Japanese businesses and encourage the use of synthetic biology to develop sustainable production processes.
- 05/14/2024
|
Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2024 Earnings Call Transcript
- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q1 2024 Earnings Conference Call May 9, 2024 5:30 PM ET Company Participants Megan LeDuc – Manager-Investor Relations Jason Kelly - Co-Founder & Chief Executive Officer Mark Dmytruk - Chief Financial Officer Conference Call Participants Rahul Sarugaser - Raymond James Matt Sykes - Goldman Sachs Mike Ryskin - Bank of America Steve Mah - TD Cowen Megan LeDuc Good evening, I'm Megan LeDuc, Manager of Investor Relations at Ginkgo Bioworks. I'm joined by Jason Kelly, our Co-Founder and CEO; and Mark Dmytruk, our CFO.
- 05/09/2024
|
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q1 Loss, Lags Revenue Estimates
- Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.08 per share a year ago.
- 05/09/2024
|
Ginkgo Bioworks Reports First Quarter 2024 Financial Results
- Ginkgo announces several initiatives to accelerate path to Adjusted EBITDA breakeven by end of 2026 Initiatives include a reduction of $200 million in annualized run-rate operating expenses by mid-2025, with anticipated substantial reduction occurring in 2024 BOSTON , May 9, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2024. The update, including a webcast slide presentation with additional details on the first quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.
- 05/09/2024
|
3 Meme Stocks to Sell in May Before They Crash & Burn
- The stock market has been on an incredible run over the past year with tech and growth stocks surging. Traders have piled into many fast-moving companies in hopes of locking in quick trading gains.
- 05/08/2024
|
Want $10,000? Invest $1,000 in These 3 Penny Stocks Now
- There's the age-old adage, “You have to spend money to make money.” But then again, what if you could spend pennies and get back dollars?
- 05/07/2024
|
GreenLab Partners with Ginkgo Bioworks to Scale Up Production of Brazzein, a Novel Sweetener
- To scale up its production of brazzein, GreenLab will leverage its proprietary technology to grow proteins inside corn kernels, optimizing its process with Ginkgo's Plant Trait Services , Protein Services , and Deployment Capabilities JONESBORO, Ark. and BOSTON , May 7, 2024 /PRNewswire/ -- GreenLab, an emerging next generation plant-biotechnology company producing complex proteins in corn, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership.
- 05/07/2024
|
Ginkgo Bioworks Announces Presentations at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
- BOSTON , May 6, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced its participation in the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 7-11, in Baltimore, MD. Ginkgo will present three posters in cell therapy and give one oral presentation in mRNA therapeutics.
- 05/06/2024
|
Ginkgo Bioworks Announces Date of First Quarter 2024 Results Presentation
- Presentation and Q&A session scheduled for post-market on Thursday, May 9, 2024 BOSTON , May 2, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2024, on Thursday, May 9, 2024, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.
- 05/02/2024
|
Ginkgo Bioworks: Buy, Sell, or Hold?
- Ginkgo Bioworks needs to keep scaling up to increase its efficiency. The challenge is it doesn't have a very long cash runway anymore.
- 04/30/2024
|
Here's why Cathie Wood's Ginkgo Bioworks (DNA) stock has dived
- Cathie Wood, the founder of Ark Invest, is under intense pressure as most of her ETFs implode. The Ark Innovation Fund (ARKK) ETF has crashed by 72% from its highest level in 2021 while the Ark Genomic Revolution ETF (ARKG) is down by 79% from the same period.
- 04/30/2024
|
Is a Giant Short Squeeze in Ginkgo Bioworks (DNA) Stock?
- Ginkgo Bioworks (NYSE: DNA ) stock has seen a recent surge in short interest combined with a jump in its share price, fueling speculation that a short squeeze is in the makings for DNA stock. Indeed, over the past few days, the number of DNA short shares available has recently sunk from around 750,000 to 0, according to financial data website Fintel.
- 04/29/2024
|
Il Granaio delle Idee and Ginkgo Bioworks Announce Strategic Collaboration to Optimize Sourdough Strains for Bakery Products
- IGDI will leverage Ginkgo's Adaptive Laboratory Evolution technology to improve its sourdough starter culture product PADUA, Italy and BOSTON , April 16, 2024 /PRNewswire/ -- Il Granaio delle Idee (IGDI), an innovative international developer and provider of clean label baking ingredients, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new collaboration. IGDI has identified a new sourdough bakery strain that can improve the flavor and aroma profile of baked goods via its starter culture product, Pater ®.
- 04/16/2024
|
Novo Nordisk and Ginkgo Bioworks Are Teaming Up. Here's Why That's Bullish for Both Stocks.
- Novo Nordisk and Ginkgo Bioworks will work together on manufacturing. Producing more obesity and diabetes medicines is likely a priority.
- 04/15/2024
|
Modalis Announces Partnership with Ginkgo Bioworks
- TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)--Modalis Therapeutics Corporation (Modalis) (Tokyo Stock Exchange: 4883) announced that it has entered into an agreement with Ginkgo Bioworks (Ginkgo) to join the Ginkgo Technology Network. This strategic alliance will enable Ginkgo's global customers in the cell and gene therapy fields to access Modalis' proprietary epigenome modulation technology, CRISPR-GNDM® (Guide Nucleotide-Directed Modulation). Modalis' CRISPR-GNDM® Technology is capable of activat.
- 04/12/2024
|
Ginkgo Bioworks Announces Acquisition of AgBiome's Platform Assets
- BOSTON , April 11, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA ), which is building the leading platform for cell programming and biosecurity, announced the acquisition of AgBiome's platform assets, including over 115,000 fully sequenced and isolated strains, over 500 million unique gene sequences, and relevant functional data and metadata, as well as AgBiome's development pipeline. These assets will be integrated into Ginkgo Ag Biologicals Services , established with the acquisition of a Bayer agricultural biologicals R&D facility in 2022, and will expand Ginkgo's proprietary unified metagenomics database.
- 04/11/2024
|
Ginkgo Bioworks Previews Today's Annual Ferment Conference, Announces "Lab Data as a Service"
- BOSTON , April 11, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA ), which is building the leading platform for cell programming and biosecurity, is hosting its 5th annual Ferment conference. The conference brings together stakeholders from across the synthetic biology community, including R&D leaders, Ginkgo Technology Network partners, experts from across academia, journalists, and many more.
- 04/11/2024
|
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
- These biotech stocks have missed out on market gains so far, falling in the double digits over the past year. But they are innovators with potential growth catalysts right around the corner.
- 04/09/2024
|
2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now?
- Analyst price targets for a pair of biotech stocks suggest they can more than double your money over the next 12 months. B. Riley recently lowered expectations for Ginkgo Bioworks, but its new target still implies more than 100% upside.
- 04/03/2024
|
AI2 Incubator spinout Modulus sells cell therapy tech assets to Boston's Ginkgo Bioworks
- The news: Modulus Therapeutics, a Seattle-based cellular therapy company spun out of the Allen Institute of Artificial Intelligence (AI2) Incubator, has sold its cell therapy platform assets to the Boston biotech company Ginkgo Bioworks.
- 04/02/2024
|
Sizing Your Penny Stocks Position, 3 Tips
- Sizing positions correctly is a cornerstone of successful investing, especially when dealing with penny stocks. The unique nature of penny stocks, with their potential for substantial gains, requires a nuanced approach to position sizing.
- 03/31/2024
|
Is Ginkgo Bioworks Stock a Buy?
- Ginkgo Bioworks is trying to make good on its promises of scaling up. It's adding plenty of new programs, but its revenue is lagging.
- 03/15/2024
|
3 Pharmaceutical Stocks to Buy Hand Over Fist in March
- Pfizer is a rebound candidate that pays a hefty dividend while you wait. AbbVie has been broadening its product offerings to become more diversified.
- 03/11/2024
|
Is Ginkgo Bioworks Destined to Be in a "Magnificent Seven" of Healthcare Stocks?
- Ginkgo Bioworks is aiming to play a key role in drug development. And there's a solid argument for why it could be hugely successful one day.
- 03/03/2024
|
Why Ginkgo Bioworks Stock Is Sinking Today
- Ginkgo Bioworks' fourth-quarter results missed Wall Street's revenue and earnings estimates. The company's full-year 2024 revenue guidance was also well below analysts' consensus estimate.
- 03/01/2024
|
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q4 Loss, Misses Revenue Estimates
- Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.04 per share a year ago.
- 02/29/2024
|
Is Ginkgo Bioworks Stock a Buy Now?
- Ginkgo's cell programming process helps businesses launch products and improve existing processes. The company has partnered with many top names in the healthcare industry for this purpose.
- 02/24/2024
|
2 Top Biotech Stocks That Wall Street Thinks Could Soon Double in Value
- Analysts are bullish, on average, regarding both Ginkgo Bioworks and Iovance Biotherapeutics. Ginkgo Bioworks' cost-cutting and manufacturing scaling capabilities are being put to the test.
- 02/23/2024
|
7 Stocks Cathie Wood Is Still Loading Up On in Q1
- You can't say Cathie Wood is afraid to make big bets. The investing guru is more than willing to lay it all on the line for stocks she believes in.
- 02/13/2024
|
2 Growth Stocks That Could Rocket 144% and 202% Higher This Year, According to Wall Street
- The average analyst following Ginkgo Bioworks thinks the stock can climb 140% from recent prices over the next 12 months or so. The consensus price target on Intellia Therapeutics suggests it can more than triple your money from recent prices.
- 01/27/2024
|
3 Healthcare Stocks at 52-Week Lows: Buy or Bye?
- Healthcare stocks trudged through what was a terrible 2023 for the sector. While the S&P 500 rose by 24% during 2023, the healthcare sector managed paltry returns of 0.3%.
- 01/26/2024
|
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought This Week
- Cathie Wood bought shares of Meta Platforms, Recursion Pharmaceuticals, and Ginkgo Bioworks this week. Shares of Meta have more than tripled since bottoming out in late 2022.
- 01/25/2024
|
3 Pricey Stocks I'll Be Watching Like a Hawk in 2024
- Eli Lilly's valuation is through the roof, but it's not just hot air. Ginkgo Bioworks could become a great long-term pickup.
- 01/14/2024
|
3 Cathie Wood Stocks to Start Off Your New Year Right
- Cathie Wood has loaded up her portfolio with tomorrow's potential healthcare game changers. The superstar investor's commitment to innovation helped her flagship fund jump more than 60% last year.
- 01/10/2024
|
Could Ginkgo Bioworks Stock Help You Become a Millionaire?
- Ginkgo Bioworks is a cell programming specialist that has partnered with many big companies. It is in a very early stage, but has a lot of promising opportunities in the long run.
- 12/24/2023
|
2 Cathie Wood Stocks That Might Be Smart Buys Right Now
- Cathie Wood's focus on disruptive technologies could be a winning strategy over the long term. Ginkgo Bioworks and Recursion Pharmaceuticals are two of her more intriguing holdings in the biotech industry.
- 12/17/2023
|
AI Meets Biotech: 3 Top Stocks Transforming Medical Science
- One of the biggest stories of the year has been the rise of AI in every industry. This trend will hit biotech stocks no less than any others.
- 12/16/2023
|
3 Dirt-Cheap Stocks to Buy Hand Over Fist Before the End of the Year
- Stocks won't automatically become more expensive when we shift into a new year. But those that have struggled this year and have strong long-term outlooks could rebound at any point.
- 12/13/2023
|
Looking for Growth? 2 Top Stocks to Buy Hand Over Fist
- These companies are just getting started along the path of revenue growth. Their technologies -- gene editing and organism engineering -- help them stand out from the crowd.
- 12/01/2023
|
7 Small-Cap Stocks to Buy BEFORE the Year-End Rally
- Small-cap stocks to buy offer a window into the future of the global economy, encapsulating companies with market capitalizations upwards of $250 million and $2.5 billion. These are the potential giants of tomorrow, starting as small-caps and gradually ascending to large or even mega-cap status through consistent earnings expansion.
- 11/30/2023
|
3 Synthetic Biology Stocks Likely to Mint New Millionaires
- Synthetic biology refers to using engineered organisms to produce products for multiple industries. Specifically, the pharmaceutical, biotechnology, and agriculture sectors are set to benefit most from synthetic biology.
- 11/29/2023
|
Where Will Ginkgo Bioworks Be in 5 Years?
- The cell programming upstart is partnering with behemoths like Pfizer and Alphabet. The business remains unproven, incurring heavy losses over the past four quarters.
- 11/24/2023
|
2024's Hidden Gems: 7 Small-Caps Set for Explosive Growth
- Finding a great small-cap stock to buy isn't always easy. We know that, over the long run, small-cap stocks as a whole outperform large-cap cousins.
- 11/23/2023
|
Ginkgo Bioworks: A Long Way To Go
- Ginkgo Bioworks' Q3 results were relatively poor due to the difficult macro environment and the winding down of its COVID testing business. While Ginkgo's Cell Engineering business has enormous potential, data indicates that this business is still nascent. Investors expecting significant downstream value will need to be patient. Progress amongst pharmaceutical and biotech customers is an important development but most of these programs are yet to be completed.
- 11/21/2023
|
3 Key Trends to Consider in Ginkgo Bioworks' Q3 Earnings Report
- Ginkgo Bioworks is successfully scaling its customer base. It's also making some progress towards profitability.
- 11/17/2023
|
3 Cutting-Edge Biotech Stocks for the Bold Investor
- Ahead of what could be significant uncertainties in the market, investors may be better served with cutting-edge biotech stocks. Fundamentally, the reasoning centers on relative insulation.
- 11/14/2023
|
Ginkgo Bioworks Holdings Inc. (DNA) Q3 2023 Earnings Call Transcript
- Ginkgo Bioworks Holdings Inc. (NYSE:DNA ) Q3 2023 Results Conference Call November 8, 2023 5:30 PM ET Company Participants Megan LeDuc - Manager of Investor Relations Jason Kelly - Founder, CEO & Director Mark Dmytruk - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Poon Mah - TD Cowen Derik Bruin - BofA Securities Michael Freeman - Raymond James E.V. Koslosky - Goldman Sachs Megan LeDuc Good evening.
- 11/10/2023
|
Why Ginkgo Bioworks Stock Was Plummeting on Thursday
- No investor likes a big earnings miss. While the biotech beat on the top line for its third quarter, that bottom-line whiff was glaring.
- 11/09/2023
|
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
- Ark Invest bought shares of Toast, Ginkgo Bioworks, and Robinhood Markets on Wednesday. The three stocks fell as much as 14% on Wednesday after disappointing quarterly results.
- 11/09/2023
|
3 No-Brainer Stocks to Buy With $50 Right Now
- No-brainer buys offer you a compelling future growth story for a great price. The idea is to make a small investment today and hold on for the long term when your patience could pay off.
- 10/31/2023
|
Porter's 5 Forces Suggest That Ginkgo Is A Buy
- Ginkgo Bioworks is analyzed based on Porter's Five Forces framework for competitive dynamics. The threat of competition in Ginkgo's R&D discovery business is low due to its unique offerings and limited number of competitors. Ginkgo has been able to convert large pharmaceutical companies onto its Foundry Platform which suggests that the threat of substitution is becoming lower and lower.
- 10/25/2023
|
Cathie Wood Just Doubled Down on This Biotech Stock. Should You Follow Her Lead?
- Ginkgo Bioworks boasts an impressive roster of clients, partners, and executives. The company's revenue is unpredictable while its cash burn is hard to ignore.
- 10/21/2023
|
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
- Ark Invest bought shares of Roku, Ginkgo Bioworks, and Archer Aviation on Wednesday. Roku hit a three-month low on Wednesday after an analyst lowered his price target on the shares a day earlier.
- 10/19/2023
|
This Cathie Wood Stock Could Soar 140%, Wall Street Says. Is That Too Optimistic?
- Famous investor Cathie Wood has been buying up shares of Ginkgo Bioworks over the past year. The company's revenue has climbed in recent years, but the share price hasn't followed.
- 10/18/2023
|
2 Growth Stocks That Could Double Your Money, According to Wall Street
- There are a couple of stocks in the healthcare sector that could climb more than 100%, according to consensus estimates from Wall Street analysts. Analysts expecting CRISPR Therapeutics to launch its first drug next year think the stock could more than double from recent prices.
- 10/15/2023
|
Ginkgo Bioworks: Products Progressing Towards Market
- Ginkgo Bioworks' stock price has been volatile due to mixed Q2 earnings, partnership announcements, and concerns about the macro environment. Antheia recently achieved a successful full-scale production run of its first product, but it is unclear how involved Ginkgo was in this achievement and whether it stands to benefit. Ginkgo's partnership with Google and the regulatory approval of Light Bio's bioluminescent plants have boosted investor sentiment, despite their uncertain impact on Ginkgo's business.
- 10/10/2023
|
3 Biotech Stocks Ready to Break Out in 2024
- While the S&P 500 remains up on the year, the biotech sector is down. Even though the broader market is showing signs of strength in areas like AI and automation, those trends haven't benefited biotech stocks as much.
- 10/07/2023
|
3 Promising Cathie Wood Stocks That Will Make Early Investors Rich
- Although the innovation space may be on the verge of a broader correction, certain ideas may pop higher, which brings us to Cathie Wood stocks to make you rich. One of the most respected names on Wall Street, Wood is the founder of ARK Invest, a global asset manager.
- 10/04/2023
|
2 Magnificent Growth Stocks to Buy Right Now
- Growth stocks are an important element of a well-balanced portfolio. Ginkgo Bioworks and Harmony Biosciences are two risky growth plays that could deliver stellar returns over the long term.
- 10/04/2023
|
3 Healthcare Stocks to Keep an Eye On
- Shockwave Medical just got a boost from a Medicare decision on one of its products. Bio-Techne is benefiting from increased cell and gene therapy revenue.
- 10/03/2023
|
Why Ginkgo Bioworks Stock Is Surging Higher Today
- Ginkgo Bioworks and Pfizer announced a new RNA therapeutics collaboration today. In response, Ginkgo Bioworks' stock jumped by double digits in early-morning trading Wednesday.
- 09/27/2023
|
These 2 Stocks Are Getting Smart Investors' Attention Wednesday
- Smart investors are looking for ways to put their money to work well. NextEra Energy Partners cut its expectations for distribution growth.
- 09/27/2023
|
DNA Stock Alert: Ginkgo Bioworks Announces Major Partnership With Pfizer
- Ginkgo Bioworks (NYSE: DNA ) stock jumped almost 14% overnight after it signed a collaboration agreement with Pfizer (NYSE: PFE ). The deal gives Ginkgo upfront cash and could eventually be worth $331 million, based on its RNA technology.
- 09/27/2023
|
Cathie Wood's Stock Shuffle: 4 Names She's Loving, 3 She's Leaving
- Cathie Wood stocks have captivated investors for years now. Wood is a popular money manager because her investing style isn't so different from many small retail investors.
- 09/27/2023
|
2 Beaten-Down Growth Stocks That Could Rocket 107% to 127% Higher, According to Wall Street
- Consensus price targets from Wall Street analysts suggest a pair of healthcare stocks can more than double your money. Hims & Hers Health runs an increasingly popular niche telehealth platform where patients can get their prescriptions written and filled.
- 09/26/2023
|
Immunomics Stocks: 3 Ways to Play This Massive AI-Biotech Megatrend
- Biotech has long seemed to move slower than its fellow tech fields due to the complexity of biological systems and the difficulty of drug regulations. However, that precedent is set to change thanks to the growing implementation of artificial intelligence ( AI ), upending the field and bringing big changes to the industry.
- 09/22/2023
|
Ginkgo Bioworks is Teaming Up With Alphabet For AI, But Does That Make It a Buy?
- Alphabet and Ginkgo Bioworks just inked a five-year AI deal. It won't solve any of Ginkgo's major issues, but it could help at the margin.
- 09/20/2023
|
The 7 Most Undervalued Cathie Wood Stocks to Buy in September 2023
- Pursuing undervalued Cathie Wood stocks radiates a magnetic allure for investors aiming for a hefty financial breakthrough. The stocks favored by Wood are risky but grounded in foresight, offering tremendous long-term upside potential.
- 09/15/2023
|
Cathie Wood Is Buying These 2 Biotech Stocks Hand Over Fist, and Wall Street Thinks They Could Double
- Cathie Wood likes to buy innovative and disruptive companies. She's been buying both Intellia Therapeutics and Ginkgo Bioworks recently.
- 09/10/2023
|
Why Ginkgo Bioworks Stock Was a 34% Winner This Week
- The biotech announced not one, but two partnerships in the past few days. One was with a top name in the tech sector.
- 09/01/2023
|
Ginkgo Bioworks CEO: Our AI model will learn to speak DNA just like ChatGPT learned English
- Jason Kelly, Ginkgo Bioworks CEO, joins 'Closing Bell Overtime' to talk partnering with Google Cloud, its AI offerings and more.
- 09/01/2023
|
Andreas Halvorsen's Firm Ups Inhibrx Stake
- Viking Global Investors, the investment firm founded by Andreas Halvorsen (Trades, Portfolio) in 1999, disclosed earlier this week it boosted its stake in Inhibrx Inc. ( INBX , Financial) by 7.71% following a private placement financing agreement.
- 09/01/2023
|
Ginkgo Bioworks: Google Partnership Increases Runway (Rating Upgrade)
- Ginkgo Bioworks Holdings has signed a five-year partnership with Google Cloud, providing funding and improving brand recognition. Ginkgo's disappointing Q2 earnings report highlights the need for additional streams of revenue and improved profitability, which the partnership with Google Cloud may help achieve. Their financial situation has become more tenable and as such we are upgrading our rating on DNA stock to neutral.
- 08/30/2023
|
DNA Stock Alert: Did Ginkgo Bioworks Just Become the Next Big AI Stock?
- One of the best-performing stocks in today's market is biotech company Ginkgo Bioworks (NYSE: DNA ). Shares of DNA stock rocketed more than 20% higher in early afternoon trading.
- 08/29/2023
|
Trading Penny Stocks This Week? 4 To Watch With Big News
- Are you trading penny stocks this week? Chances are that if you're reading this article, you have some intention of finding more info on cheap stocks.
- 08/29/2023
|
The GMO Frontier: 3 Synthetic Biology Stocks for Your Must-Buy List
- It's been more than a half century since humanity first learned to genetically modify organisms. While we're still learning new things every day about it, synthetic biology has now become commonplace in a multitude of industries.
- 08/25/2023
|
2 Growth Stocks Cathie Wood Is Buying Hand Over Fist
- Ark Invest, the firm managed by Cathie Wood, announces its activity after each trading day. Last week, Ark Invest bought millions of shares of Archer Aviation, an air taxi business that could achieve liftoff in a couple of years.
- 08/22/2023
|
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
- UiPath, Ginkgo Bioworks, and Archer Aviation were all on the Ark Invest shopping list on Thursday. UiPath has shed more than a quarter of its value since peaking in June.
- 08/18/2023
|
Why Ginkgo Bioworks Stock Plunged by 8% This Week
- The highly specialized healthcare company reported its second-quarter results. The easing of the Covid pandemic had a deleterious effect on its finances.
- 08/11/2023
|
Penny Stocks: What They Are & 3 To Watch In The Stock Market Today
- You've probably heard about penny stocks and wondered what why they ignite so much excitement. Investing in stocks that only cost pennies?
- 08/11/2023
|
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2023 Earnings Call Transcript
- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q2 2023 Earnings Conference Call August 9, 2023 5:30 PM ET Company Participants Anna Marie Wagner - Senior Vice President, Corporate Development Jason Kelly - Co-Founder and Chief Executive Officer Mark Dmytruk - Chief Financial Officer Conference Call Participants Rahul Sarugaser - Raymond James Matt Sykes - Goldman Sachs Steve Mah - Cowen Mark Massaro - BTIG Anna Marie Wagner Good evening. I am Anna Marie Wagner, SVP of Corporate Development at Ginkgo Bioworks.
- 08/10/2023
|
Ginkgo Bioworks up 7% in pre-market after inking second Merck deal
- Shares in Ginkgo Bioworks jumped more than 7% in pre-market trading following the announcement of their collaboration with Merck & Co Inc (NYSE:MRK). The partnership aims to enhance biologics manufacturing.
- 08/07/2023
|
Ginkgo Bioworks up 6% in pre-market after inking second Merck deal
- Shares in Ginkgo Bioworks jumped more than 7% in pre-market trading following the announcement of their collaboration with Merck & Co Inc (NYSE:MRK). The partnership aims to enhance biologics manufacturing.
- 08/07/2023
|
Ginkgo Bioworks stock pops as company plans Merck collaboration
- Ginkgo Bioworks Holdings Inc. shares DNA, were rising more than 5% in Monday's premarket trading after the company said it was collaborating with Merck & Co. Inc. MRK, -0.69% on improvements in biologic manufacturing. Ginkgo plans to use its abilities in cell engineering, ultra high-throughput multiplexed screening, protein characterization and process optimization to boost yields and drive improvements in production efficiency.
- 08/07/2023
|
3 Growth Stocks Cathie Wood Is Betting On Now: August 2023
- The renowned investor and founder of Ark Invest, Cathie Wood, has set her sights on three disruptive growth stocks that may soon redefine their respective industries. The first stock is a semiconductor company with a promising future amid industry challenges.
- 08/04/2023
|
Ginkgo Bioworks Announces Date of Second Quarter 2023 Results Presentation
- Presentation and Q&A session scheduled for post-market on Wednesday, August 9, 2023 BOSTON , Aug. 2, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the second quarter ended June 30, 2023, on Wednesday, August 9, 2023, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.
- 08/02/2023
|
2 Cathie Wood Stocks That Could Be Hidden Gems
- Cathie Wood has positions in several leading genomic medicine companies. Prime Medicine and Ginkgo Bioworks could be two of her fund's biggest winners in the years to come.
- 07/25/2023
|
3 Cutting-Edge Biotech Stocks That Are Riding the AI Wave Like None Other
- Recursion Pharmaceuticals just got Nvidia on board with its vision of AI for R&D. Ginkgo Bioworks is pairing AI with laboratory robotics to streamline R&D, too.
- 07/21/2023
|
5 Penny Stocks To Watch Under $5 This Week
- Picture this: you're sat with a pile of ‘pennies' in your hand, and you're daydreaming about turning those pennies into dollars. Not in the usual sense, though, you're thinking about penny stocks.
- 07/19/2023
|
2 Growth Stocks Wall Street Analysts Think Can Double in Value
- Viridian has a treatment for thyroid eye disease in the works that could be a potential blockbuster. Ginkgo Bioworks programs cells and has huge opportunities in many different industries.
- 07/19/2023
|
DNA Stock Alert: The $18 Milion Reason Ginkgo Bioworks Is Up Today
- Ginkgo Bioworks (NYSE: DNA ) stock is rising higher on Wednesday after the company won a contract from the Defense Advanced Research Projects Agency (DARPA). This contract is worth $18 million over a four-year period and has Ginkgo Bioworks joining DARPA's Reimagining Protein Manufacturing ( RPM ) project.
- 07/19/2023
|
Cathie Wood Is Buying These 3 Growth Stocks Hand Over Fist. Should You?
- Cathie Wood recently added more than a million shares of a synthetic biology company called Ginkgo Bioworks to the Ark Innovation ETF. PagerDuty's automated tech-support platform is a hit with big enterprise customers from tech and non-tech industries.
- 07/15/2023
|
Best Penny Stocks to Buy? 5 To Watch With Big News
- Something that has become one of the go-tos for traders is stock market news. That goes for anything from penny stocks to mega-caps like Apple or Tesla.
- 07/13/2023
|
Why These 3 Stocks Are the Worst Ways to Play Biotech Right Now
- The tech and growth segments of the market have been having a tremendous 2023 with one glaring exception. Traders have been choosing to avoid biotech stocks amid macroeconomic uncertainty around the sector.
- 07/13/2023
|
Best Penny Stocks To Watch? 4 Under $5 For Your List
- Are you looking for the best penny stocks to watch right now? With all of the excitement in the stock market today, you're not alone.
- 07/12/2023
|
3 Top Penny Stocks to Watch With Big News This Week
- Are you looking for penny stocks to buy right now? You're not alone and there are plenty of ways to find the best penny stocks to buy.
- 07/11/2023
|
DNA Stock Alert: Ginkgo Bioworks Moves Forward With Novo Nordisk Partnership
- Ginkgo Bioworks (NYSE: DNA ) stock is on the move Tuesday after the company announced a continued partnership with Novo Nordisk (NYSE: NVO ). These two companies have been working together on the development of expression systems for pharmaceutical products.
- 07/11/2023
|
Are Penny Stocks Worth It? 3 To Watch Right Now
- Picture this: you're holding a golden ticket that could multiply your modest investment into a colossal windfall—almost overnight. It sounds like a fairytale, right?
- 06/28/2023
|
2 Growth Stocks Wall Street Thinks Can Soar 90%
- Plug Power and Ginkgo Bioworks are two long-term plays with significant growth potential. According to analysts' price targets, these stocks could nearly double in value.
- 06/22/2023
|
3 Reasons Why Cathie Wood Is Buying Ginkgo Bioworks Stock Hand Over Fist
- Cathie Wood is continuing to buy shares of Ginkgo Bioworks. The biofoundry's platform is scaling up, and customers are flocking.
- 05/23/2023
|
7 Top Penny Stocks To Buy According To Insiders In May 2023
- If you're curious about penny stocks, they offer an interesting niche. Whether you're new to trading these stocks or expanding your investment style, understanding what to look for and how to build a strong watch list is obviously important.
- 05/23/2023
|
4 Top Penny Stocks To Buy According To Insiders In May 2023
- When it comes to investing, penny stocks have become an interesting niche. If you're new to trading these types of stocks, it's important to understand what your looking for and how to find it in order to put together a strong list of penny stocks to watch.
- 05/22/2023
|
Hero or Zero? 3 High-Risk Biotech Stocks to Make You Rich
- These biotech stocks are swinging for the fences. They may hit homers, they may strike out.
- 05/22/2023
|
3 Key Biotech Trends for 2023 And Beyond
- Artificial intelligence is becoming an important value-add for collaborations. Some companies are pursuing collaboration-targeted business models.
- 05/19/2023
|
Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2023 Earnings Call Transcript
- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Anna Marie Wagner - Senior Vice President, Corporate Development Jason Kelly - Co-Founder & Chief Executive Officer Mark Dmytruk - Chief Financial Officer Conference Call Participants Gaurav Goparaju - Berenberg Bank Ivy Kozlowski - Goldman Sachs Anna Marie Wagner Good afternoon. I'm Anna Marie Wagner, SVP of Corporate Development at Ginkgo Bioworks.
- 05/10/2023
|
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q1 Loss, Tops Revenue Estimates
- Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.05 per share a year ago.
- 05/10/2023
|
DNA Stock Earnings: Ginkgo Bioworks Misses EPS, Beats Revenue Estimates
- Ginkgo Bioworks (NYSE: DNA ) just reported first quarter results for 2023. Ginkgo Bioworks reported a loss per share of 11 cents.
- 05/10/2023
|
Best Penny Stocks To Buy Now? 4 To Watch Before May CPI Data
- Are these the best penny stocks to buy right now? Here's what's moving on Monday.
- 05/08/2023
|
Down 76% From Its High, Can Ginkgo Bioworks Stock Turn Things Around?
- The bio-engineering companyexpects a sharp slowdown in revenue this year. Despite all of its partnerships, Ginkgo's business isn't overly diverse, suggesting it could have a hard time handling an economic downturn.
- 05/04/2023
|
7 Best Cathie Wood Stocks for Your May 2023 Buy List
- Cathie Wood invests in speculative stocks that don't always pan out, as 2022 showed. The chief of Ark Investment Management watched her firm outperform in 2021, though last year saw a sharp deceleration in interest in various hough-growth names.
- 05/02/2023
|
Despite Its Falling 92%, Cathie Wood Is Buying More of This Growth Stock
- Ginkgo Bioworks still needs to prove its core business model. Ginkgo doesn't have any shortage of customers, and more are likely on the way.
- 05/01/2023
|
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
- Cathie Wood bought shares of Roku, Tesla, and Ginkgo Bioworks on Thursday. Roku and Tesla are beating the market this year, but Tesla fell sharply on Thursday after posting troublesome financial results.
- 04/21/2023
|
3 Growth Stocks to Buy for 100% Returns
- Last year was a rough one for growth stocks, as investors shied away from risk in the face of rising interest rates. But in 2023, investors are once again on the hunt for companies with above-average growth rates.
- 04/11/2023
|
How to Navigate Penny Stock Downtrends, 3 Tips and Tricks
- Here's what you need to know about making money with penny stocks during a market downtrend The post How to Navigate Penny Stock Downtrends, 3 Tips and Tricks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/09/2023
|
Cathie Wood Loads Up On Biotech Stocks — Continues To Raise Stake In Coinbase Global
- Cathie Wood-led ARK Investment Management raised stakes in a number of biotech companies on Wednesday with these stocks recording negative returns over the last one month, potentially making them attractive in terms of valuations.
- 04/06/2023
|
Sensible Biotechnologies And Ginkgo Bioworks Announce Partnership To Make In Vivo RNA To Unlock The Promise Of RNA Therapeutics
- Coaxing cells to produce mRNA for therapeutic applications has been an unsuccessful endeavor so far. Miroslav Gasparek is on a mission to use synbio to change that.
- 04/03/2023
|
This Growth Stock Is Down 63% in 1 Year. Here's Why You Should Buy the Dip and Hold It for 5 Years
- Ginkgo Bioworks is improving its efficiency and building its clientele. Nonetheless, its coronavirus diagnostic revenue is falling and unlikely to recover.
- 03/29/2023
|
Penny Stocks Trading: Tips for Setting Realistic Investing Goals
- Setting penny stocks investing goals? Use these 3 top tips The post Penny Stocks Trading: Tips for Setting Realistic Investing Goals appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 03/14/2023
|
Buy the Dip: 2 Exceptional Growth Stocks to Grab Before the Next Bull Market
- Growth stocks took the brunt of the bear market's decline, but now there's opportunity. Ginkgo has carved out a very specialized and needed niche in the biotech world.
- 03/05/2023
|
Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2022 Earnings Call Transcript
- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET Company Participants Anna Marie Wagner - SVP, Corporate Development Jason Kelly - Co-Founder & CEO Mark Dmytruk - CFO Conference Call Participants Matthew Sykes - Goldman Sachs Rahul Sarugaser - Raymond James Tejas Savant - Morgan Stanley Steve Mah - Cowen Madeline - William Blair Mark Massaro - BTIG Anna Marie Wagner Good afternoon. This is Anna Marie Wagner, SVP of Corporate Development at Ginkgo Bioworks.
- 03/01/2023
|
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q4 Loss, Tops Revenue Estimates
- Ginkgo Bioworks Holdings, Inc. (DNA) delivered earnings and revenue surprises of 86.67% and 16.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/01/2023
|
This Biotech Is Already Using AI, but Is the Growth Stock a Buy?
- Few biotechs can claim to be using AI in as central of a role as Ginkgo Bioworks.
- 02/24/2023
|
Is It Too Early to Invest in Ginkgo Bioworks?
- Ginkgo is on track to easily beat its guidance for 2022. But what about its bottom line?
- 02/22/2023
|
The Next Big Disruptors? 3 Biotech Stocks Making Headlines.
- Since the biotech bonanza of the pandemic era, many biotech stocks have rocketed up and then down in price. Ginkgo Bioworks (NYSE: DNA ), Twist Bioscience (NASDAQ: TWST ), and Amyris (NASDAQ: AMRS ) all fell more than 75% from peak to trough, and may still have farther to fall.
- 02/17/2023
|
Microbial Immunotherapy Company Prokarium Raises $30M On Heels Of Ginkgo Bioworks Partnership
- the next time you think Salmonella, think Prokarium. These bacteria may cause food poisoning in one form, but engineered the right way can become living medicine — turning not fuel into fire but fire into fuel.
- 02/09/2023
|
Ginkgo: Standardizing Offerings For Growth
- Ginkgo is working to standardize its offerings and streamline the sales process by establishing an easily accessible set of offerings, standardizing key aspects. So far, the financial results showed growth and diversification in the cell programming business, with 15 new cell programs added to the platform.
- 02/08/2023
|
3 Cathie Wood Stocks That Could More Than Double in 12 Months, According to Wall Street
- These stocks are risky. But they just might deliver huge gains if analysts are right.
- 02/07/2023
|
Ginkgo Bioworks Fires Up Its Bio Foundry To Take On The Billion-Dollar Enzyme Market
- Enzymes are a multi-billion dollar market and growing. But engineering enzymes is not an easy task.
- 01/24/2023
|
4 Short Squeeze Penny Stocks To Watch In January 2023; Time To Buy?
- Short squeeze penny stocks to watch this month. The post 4 Short Squeeze Penny Stocks To Watch In January 2023; Time To Buy?
- 01/13/2023
|
How to Increase Your Chances of Consistent Penny Stocks Profits
- Use these tips to make money with penny stocks The post How to Increase Your Chances of Consistent Penny Stocks Profits appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/01/2023
|
Three Pharma Stocks to Sell Before They Die
- As we head into New Year 2023, we wanted to take a look at some of the top biotech blunders of the last several months. While many biotech stocks can hold immense profit potential, others can wipe out your accounts in the blink of an eye.
- 12/24/2022
|
Down 76% This Year, Is This Growth Stock Now a Screaming Buy?
- The company's strategy will take time to implement, but it'll make investors a lot richer if it works.
- 12/06/2022
|
10 Top Penny Stocks With Unusual Options Activity, Time To Buy?
- Penny stocks to watch with unusual options activity this week. The post 10 Top Penny Stocks With Unusual Options Activity, Time To Buy?
- 11/22/2022
|
Are Penny Stocks too Risky to Invest In? 3 Reasons to Consider
- Check out these reasons to buy penny stocks in 2022 The post Are Penny Stocks too Risky to Invest In? 3 Reasons to Consider appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 11/21/2022
|
7 Top Penny Stocks With Unusual Options Activity, Time To Buy?
- Penny stocks to watch with unusual options activity this week. The post 7 Top Penny Stocks With Unusual Options Activity, Time To Buy?
- 11/18/2022
|
Cathie Wood Keeps Buying Ginkgo Bioworks (DNA) Stock
- This week has proven to be a rough one for investors in Ginkgo Bioworks (NYSE: DNA ) stock. After announcing a $100 million public offering, DNA stock has lost more than 20% of its value in the past five days alone.
- 11/18/2022
|
Ginkgo Bioworks: Strange Equity Offering
- Company announces $100 million equity offering. Q3 revenues beat and yearly forecast raised.
- 11/16/2022
|
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2022 Earnings Call Transcript
- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Anna Marie Wagner - Senior Vice President-Corporate Development Jason Kelly - Co-Founder and Chief Executive Officer Mark Dmytruk - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Rahul Sarugaser - Raymond James Matt Sykes - Goldman Sachs Steve Mah - Cowen Mark Massaro - BTIG Anna Marie Wagner Good afternoon. This is Anna Marie Wagner, SVP of Corporate Development at Ginkgo Bioworks.
- 11/14/2022
|
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q3 Loss, Tops Revenue Estimates
- Ginkgo Bioworks Holdings, Inc. (DNA) delivered earnings and revenue surprises of -60% and 22.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/14/2022
|
3 Beginner Penny Stocks Trading Mistakes
- Check these strategies out for buying penny stocks right no The post 3 Beginner Penny Stocks Trading Mistakes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 10/30/2022
|
3 Unstoppable Stocks That Could Double in 5 Years
- The opportunities for these innovators are tremendous.
- 10/29/2022
|
3 Hot Penny Stocks To Buy Under $3 With Must Read News
- Penny stocks to watch with news today. The post 3 Hot Penny Stocks To Buy Under $3 With Must Read News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 10/25/2022
|
Using Volatility to Make Money With Penny Stocks
- How using volatility can help to profit with penny stocks The post Using Volatility to Make Money With Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 10/24/2022
|
Can Acquisitions and Partnerships Take Ginkgo Bioworks (DNA) Stock Higher?
- Ginkgo Bioworks (NYSE: DNA ) stock has been making headlines left and right this month. The company has announced several new collaborations and acquisitions.
- 10/20/2022
|
Ignore the Hype! These Are 7 of the Worst Stocks to Own Now
- This has been a rough year for stocks. Every time the market has tried to bounce, some fresh news has come out, triggering another selloff.
- 10/20/2022
|
Cathie Wood's Firm Expands Shopify and Gingko Bioworks Holdings in 3rd Quarter
- ARK Investment Management, the disruptive innovation firm founded by Catherine Wood (Trades, Portfolio), disclosed in a regulatory filing that its top five trades during the third quarter included boosts to its holdings in Shopify Inc. ( SHOP , Financial) and Gingko Bioworks ( DNA , Financial) and reductions of its holdings in Signify Health ( SGFY , Financial), Spotify Technology SA ( SPOT , Financial) and Stratasys Ltd. ( SSYS , Financial).
- 10/18/2022
|
What Is Going on With Ginkgo Bioworks (DNA) Stock Today?
- It's an unforgettable day for Ginkgo Bioworks (NYSE: DNA ) as the company just disclosed a deal with pharmaceutical giant Merck (NYSE: MRK ). Together, the two companies hope to innovate pharmaceutical manufacturing processes through the use of enzyme technology.
- 10/11/2022
|
5 Penny Stocks To Watch With Big News Is The Stock Market Today
- 5 penny stocks to watch this week. The post 5 Penny Stocks To Watch With Big News Is The Stock Market Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 10/11/2022
|
Co-founders Keep Buying Ginkgo Bioworks (DNA) Stock
- Source: Connect world / Shutterstock.com Ginkgo Bioworks (NYSE: DNA ) stock is in full focus today following ownership updates from three co-founders. The cell programming company has become a favorite of Ark Invest's Cathie Wood.
- 10/06/2022
|
Ginkgo Bioworks: Business Model Uncertainty
- Pursuing a horizontal platform strategy before the synthetic biology industry develops creates a risk of insufficient demand. Ginkgo's ability to capture downstream value is promoted, but companies like Synlogic and Cronos have not inspired confidence so far.
- 10/05/2022
|
2 Promising Growth Stocks Trading Under $10 a Share
- These stocks have plenty of room to get a whole lot bigger in the years ahead.
- 10/05/2022
|
Want to Invest Like Cathie Wood? Use These 3 Principles.
- ARK Invest's strategy emphasizes the power of innovation, even if it's risky and pricey to invest in.
- 10/02/2022
|
5 Top Stocks Cathie Wood Is Buying This Week
- Last week, Cathie Wood made headlines after it was announced that she would relinquish her position as portfolio manager over two of her exchange-traded funds (ETFs), the 3D Printing ETF (BATS: PRNT ) and the ARK Israel Innovative Technology ETF (BATS: IZRL ). This led to speculation that the 66-year old Wood could soon step away from the investing world.
- 09/30/2022
|
Why Shares of Ginkgo Bioworks Bounded Higher This Week
- This synbio stock was on the ARK funds' shopping list this week.
- 09/30/2022
|
3 Growth Stocks That Could Double Your Money, According to Wall Street
- Price targets on these stocks are miles above their present market values.
- 09/29/2022
|
4 Alzheimer's Penny Stocks To Watch After Biogen Stock Explodes
- Penny stocks to buy [or avoid] after Biogen Alzheimer's news. The post 4 Alzheimer's Penny Stocks To Watch After Biogen Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 09/28/2022
|
Ginkgo Bioworks: Promising Upside But Not Without Risks
- The company has a near-term revenue driver in the form of the Joyn Bio deal and the fertilizer shortage. On the financial side, the balance sheet is in superb form given the stage of the company's development.
- 09/28/2022
|
14 Ailing Companies Are About To Lose An Obscene Amount Of Money
- S&P 500 investors hate companies that lose money right now. So it's wise to know which companies are on the verge of losing obscene amounts so you don't end up holding the bag.
- 09/27/2022
|
Could Warren Buffett and Cathie Wood Agree on Buying This Growth Stock?
- It's possible the Oracle of Omaha would want to get on board for this stock, but not for at least a few years.
- 09/15/2022
|
Ginkgo Bioworks: May The Ginkgo King Grow
- Ginkgo Bioworks is, along with Amyris, the leader in synthetic biology. A one-of-a-kind business model, solid technology and platform, a wide range of markets and applications, compounding potential, a reasonable valuation, and minimal cash burn, make Ginkgo attractive.
- 09/13/2022
|
This Cathie Wood Stock Could Double Within 3 Years -- Here's How
- Ginkgo Bioworks is expanding so quickly that it could slow down a lot and still two times.
- 09/13/2022
|
5 Top Stocks Cathie Wood Is Buying This Week
- Shares of Cathie Wood's flagship exchange-traded fund (ETF), the ARK Innovation ETF (NYSEARCA: ARKK ), finished the week in the green, driven by gains in high-growth names and the overall market. However, two major catalysts loom on the horizon.
- 09/09/2022
|
10 Top Penny Stocks With Unusual Options Activity This Week
- Penny stocks to watch today with unusual options action. The post 10 Top Penny Stocks With Unusual Options Activity This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 09/08/2022
|
Don't Jump Into the Deepening Financial Hole with Ginkgo Bioworks
- Boston-based Ginkgo Bioworks (NYSE: DNA ) is a biotechnology company that's advancing a platform for cell programming. Reportedly, famous ARK Invest fund manager Cathie Wood bought a large stake in DNA stock not long ago.
- 08/29/2022
|
3 Stocks That Can Double Your Money According to Wall Street
- The experts say these stocks aren't getting half the appreciation that they deserve.
- 08/29/2022
|
5 Cathie Wood Stocks Signaling “The Bear Market Is Over”
- This article is excerpted from Tom Yeung's Profit & Protection newsletter dated Aug. 16, 2022. To make sure you don't miss any of Tom's picks, subscribe to his mailing list here.
- 08/22/2022
|
3 Monster Stocks in the Making to Buy Right Now
- These stocks have the potential to be huge winners for investors over the long term.
- 08/20/2022
|
Cathie Wood Is Doubling Down on Ginkgo Bioworks (DNA) Stock
- Cathie Wood's infatuation with Ginkgo Bioworks (NYSE: DNA ) stock continued this week. The ARK Invest fund manager purchased an additional 1.13 million shares of the gene editing company on Thursday, adding to her already sizable holdings of DNA stock.
- 08/19/2022
|
Why Ginkgo Bioworks Stock Blasted 7% Higher Today
- Investors warmly greeted the company's latest quarterly earnings report.
- 08/16/2022
|
Ginkgo Bioworks Holdings, Inc. (DNA) CEO Jason Kelly on Q2 2022 Results - Earnings Call Transcript
- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Anna Marie Wagner – Senior Vice President-Corporate Development Jason Kelly – Co-Founder and Chief Executive Officer Mark Dmytruk – Chief Financial Officer Conference Call Participants Matt Sykes – Goldman Sachs Matt Larew – William Blair Tejas Savant – Morgan Stanley Steve Mah – Cowen Rahul Sarugaser – Raymond James Vivian Bais – BTIG Anna Marie Wagner Good afternoon. This is Anna Marie Wagner, SVP of Corporate Development at Ginkgo Bioworks.
- 08/15/2022
|
Hot Penny Stocks to Add to Your Watchlist Right Now
- Here's what you need to know about trading penny stocks on August 15th The post Hot Penny Stocks to Add to Your Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 08/15/2022
|
10 Stocks That Could Rise 10x (Safely)
- This article is excerpted from Tom Yeung's Profit & Protection newsletter dated Aug. 9, 2022. To make sure you don't miss any of Tom's picks, subscribe to his mailing list here.
- 08/10/2022
|
Ginkgo Bioworks: Time To Buy
- There is a developing animosity towards manufactured nitrogen fertilizers amongst the ruling classes. Many well-known politicians are extolling the virtues of avoiding farmed meat products.
- 08/10/2022
|
Should You Really Be Buying Beaten-Down Growth Stocks Right Now?
- Now's a great time to invest in companies with the potential to grow significantly in the long term.
- 08/05/2022
|
Why Biotech Disruptor Ginkgo Bioworks Is Well-Positioned for the Future
- Beaten down from its highs late last year, cell engineering company Ginkgo Bioworks now looks primed to divide and conquer.
- 08/05/2022
|
Why Ginkgo Bioworks (DNA) Is Buying Zymergen For $300 Million
- Ginkgo Bioworks (DNA) announced it entered into a definitive agreement under which Ginkgo will acquire Zymergen. These are the details.
- 07/25/2022
|
5 Top Stocks Cathie Wood Bought This Week
- Cathie Wood is still buying the dip and believes that deflationary forces may soon show out. Here are five top stocks she bought this week.
- 07/15/2022
|
Cathie Wood Just Doubled Down on Ginkgo Bioworks (DNA) Stock
- While Ginkgo Bioworks may be a relatively unknown name to many investors, DNA stock is quite well-known to Cathie Wood and her Ark funds. The post Cathie Wood Just Doubled Down on Ginkgo Bioworks (DNA) Stock appeared first on InvestorPlace.
- 07/13/2022
|
Ginkgo Bioworks: Multiple Layers Of Uncertainty
- Ginkgo has large ambitions and a valuation to match, but the company faces technology and business model risks. The stock's recent poor performance is likely due to valuation concerns and poor sentiment towards the biotech sector in general, rather than any Ginkgo specific issues.
- 07/13/2022
|
Hot Penny Stocks to Buy Today? Check These 3 For Your July List
- Can these penny stocks make gains this week? The post Hot Penny Stocks to Buy Today?
- 07/08/2022
|
Check These 3 Penny Stocks Out For Your Watchlist
- Which penny stocks are you watching right now? The post Check These 3 Penny Stocks Out For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/07/2022
|
Billionaire Andreas Halvorsen Just Bought DNA Stock. Here's Why.
- DNA stock is surging higher today following large purchases from Viking Global's Andreas Halvorsen and Ark Invest's Cathie Wood. The post Billionaire Andreas Halvorsen Just Bought DNA Stock.
- 07/07/2022
|
Beware These 7 Penny Stock Bubbles Getting Ready to Burst
- The following penny stocks have built up a large bubble that is yet to burst. They are likely to burst soon due to the market decline.
- 07/06/2022
|
Cathie Wood Is Making a Big Bet on Gingko Bioworks (DNA) Stock
- Cathie Wood's Ark Invest has purchased more than 3.5 million shares of DNA stock since June 29, its first purchases in over a month. The post Cathie Wood Is Making a Big Bet on Gingko Bioworks (DNA) Stock appeared first on InvestorPlace.
- 07/05/2022
|
Can These Penny Stocks to Watch Continue to Climb?
- Are these penny stocks on your watchlist right now? The post Can These Penny Stocks to Watch Continue to Climb?
- 06/23/2022
|
Why Ginkgo Bioworks Shares Are Rising After Announcement With Partner Cronos Group
- Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading higher by 7.63% to $2.68 after the company, and Cronos Group Inc (NASDAQ: CRON), announced the achievement of the third target productivity milestone in their partnership to produce eight cultured cannabinoids. Using Ginkgo's platform.
- 06/23/2022
|
3 Good Penny Stocks to Watch During the Market Crash
- Here are three penny stocks to add to your watchlist now The post 3 Good Penny Stocks to Watch During the Market Crash appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/13/2022
|
3 Stocks Down 50% or More That You Can Buy Right Now
- Huge rebounds could be in store for these beaten-down stocks.
- 06/11/2022
|
Ginkgo Bioworks Announces Participation in Goldman Sachs 43rd Annual Global Healthcare Conference
- BOSTON , June 10, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in Goldman Sachs' 43rd Annual Global Healthcare Conference, on June 15, 2022, at 10:40 a.m. PT. Further details, a webcast link, and a replay of the presentation, if available, will be posted on the company's investor relations website at https://investors.ginkgobioworks.com/events.
- 06/10/2022
|
Top Penny Stocks to Watch in Early June 2022
- Which penny stocks are you watching right now? The post Top Penny Stocks to Watch in Early June 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/05/2022
|
Hot Penny Stocks to Watch as May Ends
- Here are three penny stocks to add to your watchlist right now The post Hot Penny Stocks to Watch as May Ends appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/27/2022
|
Best Penny Stocks to Buy as May Ends? 3 to Watch Right Now
- Check these penny stocks out for your watchlist The post Best Penny Stocks to Buy as May Ends? 3 to Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/25/2022
|
Best Penny Stocks To Buy According To 4 Analysts & Targets Up To $8
- Best penny stocks to buy according to analysts. The post Best Penny Stocks To Buy According To 4 Analysts & Targets Up To $8 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/23/2022
|
Better Buy: Gingko Bioworks vs. Amyris
- Which of these fallen stocks has the best chance of recovery?
- 05/22/2022
|
Cathie Wood Keeps Buying Gingko Bioworks (DNA) Stock
- Shares of DNA stock are in focus following Ark Invest's buying spree this month. In the past two days, Ark has purchased 4.5 million shares.
- 05/20/2022
|
Why These Penny Stocks Climbed on May 19th, 2022
- Can penny stocks show positive momentum in May? The post Why These Penny Stocks Climbed on May 19th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/19/2022
|
Ginkgo Bioworks Holdings, Inc. (DNA) CEO Jason Kelly on Q1 2022 Results - Earnings Call Transcript
- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Anna Marie Wagner - SVP of Corporate Development Jason Kelly - Co-Founder & CEO Mark Dmytruk - CFO Conference Call Participants Matt Sykes - Goldman Sachs Tejas Savant - Morgan Stanley Rahul Sarugaser - Raymond James Mark Massaro - BTIG Steve Mah - Cowen Derik De Bruin - Bank of America Anna Marie Wagner Good afternoon. This is Anna Marie Wagner, SVP of Corporate Development at Ginkgo Bioworks.
- 05/16/2022
|
Why Ginkgo Bioworks Stock Is Falling After Hours
- Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading lower in Monday's after-hours session after the company reported financial results. Ginkgo Bioworks said first-quarter revenue increased 282% year-over-year to $168 million, which beat the $105.68-million estimate, according.
- 05/16/2022
|
What to Know About Buying Penny Stocks on May 16th
- Here's what you need to know about trading penny stocks on May 16th The post What to Know About Buying Penny Stocks on May 16th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/16/2022
|
Penny Stocks To Buy In May? 3 To Watch Before Next Week
- Penny Stocks to Buy? Here are a few for your watch list.
- 05/13/2022
|
Ginkgo Bioworks' Animal-Free Eggs Make DNA Stock Enticing
- Ginkgo's animal-free eggs deal with Evo food could be just what its overlooked stock needed to reach its full potential. DNA stock is a buy.
- 05/12/2022
|
7 Growth Stocks to Buy on the Dip
- Although the wave of red ink in the major indices is intimidating, it also presents an intriguing opportunity for growth stocks to buy. The post 7 Growth Stocks to Buy on the Dip appeared first on InvestorPlace.
- 05/10/2022
|
2 Falling Knives to Catch
- The majority of analysts on Wall Street recommend buying Better Therapeutics Inc. ( BTTX , Financial) and Ginkgo Bioworks Holdings Inc. ( DNA , Financial) shares. That is surprising given these two stocks haven't performed well over the past 52 weeks ending May 10.
- 05/10/2022
|
Ginkgo Bioworks Announces Date of First Quarter 2022 Results Presentation
- Presentation and Q&A session scheduled for post-market on Monday, May 16, 2022 BOSTON , May 9, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2022, on Monday, May 16, 2022, beginning at 4:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.
- 05/09/2022
|
Check These 3 Hot Penny Stocks Out For Your Watchlist
- Which penny stocks are you watching right now? The post Check These 3 Hot Penny Stocks Out For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/03/2022
|
3 Penny Stocks to Watch During the Stock Market Crash
- Check these three penny stocks out as the stock market falls The post 3 Penny Stocks to Watch During the Stock Market Crash appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/02/2022
|
3 Beaten-Down Stocks That Could Deliver 5X Gains By 2030
- These stocks are losers now. But they could be huge winners over the next few years.
- 05/02/2022
|
10 Top Penny Stocks Cathie Wood ARK Invest Owns, Time To Buy?
- Are these Cathie Wood penny stocks a buy right now? The post 10 Top Penny Stocks Cathie Wood ARK Invest Owns, Time To Buy?
- 04/28/2022
|
Cathie Wood Keeps Buying Gingko Bioworks (DNA) Stock. Here's Why.
- DNA stock is in the spotlight after Ark Invest reported purchasing more than 1.5 million shares this week. So, who else is betting big on Ginkgo?
- 04/27/2022
|
7 Biggest Loser Stocks That Could Become Surprising Buys
- While going contrarian is always a risky concept, these biggest loser stocks could bounce higher with the negativity priced in. The post 7 Biggest Loser Stocks That Could Become Surprising Buys appeared first on InvestorPlace.
- 04/27/2022
|
3 Stocks Cathie Wood Is Buying That Should Be on Your List, Too
- Revenue growth is soaring -- and this could be just the beginning.
- 04/16/2022
|
Why Is Ginkgo Bioworks (DNA) Stock Up Today?
- Biotechnology company Ginkgo Bioworks has a host of promising collaboration announcements. DNA stock is up as a result.
- 04/13/2022
|
Elanco, Ginkgo Bioworks Launch BiomEdit, Microbiome-Focused Animal Health Firm
- Elanco Animal Health Incorporated (NYSE: ELAN) and Ginkgo Bioworks Holdings Inc (NYSE: DNA) have launched BiomEdit, a microbiome innovation company. BiomEdit will discover, develop and introduce novel probiotics, bioactive molecules, engineered microbial medicines, and.
- 04/11/2022
|
3 Things About Ginkgo Bioworks That Smart Investors Know
- You'll have to put in some work to appreciate this stock's alluring nuances.
- 04/01/2022
|
Here's Why Ginkgo Bioworks Shares Are Rising
- Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading higher by 22.0% at $4.56 after the company reported better-than-expected fourth-quarter sales results and issued FY22 sales guidance above analyst estimates. Ginkgo Bioworks reported quarterly sales of $148.00 million which beat the.
- 03/29/2022
|
Ginkgo Bioworks Shares Gain As Q4 Sales, FY22 Guidance Surpass Street Expectations
- Ginkgo Bioworks Holdings Inc (NYSE: DNA) reported Q4 FY21 sales of $148.5 million, up 363% Y/Y, beating the consensus of $94.81 million. "The current market environment provides challenges and opportunities, but I've never been more excited about Ginkgo's future," said.
- 03/29/2022
|
Ginkgo Bioworks Holdings, Inc. (DNA) CEO Jason Kelly on Q4 2021 Results - Earnings Call Transcript
- Ginkgo Bioworks Holdings, Inc. (DNA) CEO Jason Kelly on Q4 2021 Results - Earnings Call Transcript
- 03/29/2022
|
Why Ginkgo Bioworks Stock Is Rising After Hours
- Ginkgo Bioworks Holdings Inc (NYSE: DNA) is trading higher in Monday's after-hours session after the company reported financial results and issued guidance above estimates. Ginkgo Bioworks said fourth-quarter revenue increased 363% year-over-year to $148 million, which beat the $94.
- 03/28/2022
|
These 3 Penny Stocks Climbed Today, Here's Why
- Did you catch these three popular penny stocks today? The post These 3 Penny Stocks Climbed Today, Here's Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 03/23/2022
|
3 Hot Reddit Penny Stocks to Add to Your Watchlist Right Now
- Are these Reddit penny stocks on your watchlist right now? The post 3 Hot Reddit Penny Stocks to Add to Your Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 03/22/2022
|
Top Penny Stocks To Buy Right Now? 4 Short Squeeze Stocks To Watch
- Short squeeze penny stocks to watch right now. The post Top Penny Stocks To Buy Right Now?
- 03/18/2022
|
Is Ginkgo Bioworks a Warren Buffett Stock?
- If it can become the go-to collaborator for its specialty, yes.
- 03/17/2022
|
Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2021 Results Presentation and Date for Annual Meeting of Shareholders
- Presentation and Q&A session scheduled for post-market on Monday, March 28, 2022 BOSTON , March 17, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2021, on Monday, March 28, 2022, beginning at 4:30 p.m. ET. The presentation details and webcast registration link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com and a replay will be made available.
- 03/17/2022
|
3 Unstoppable Growth Stocks to Buy in 2022 and Beyond
- There is no shortage of opportunities for these businesses to get much bigger in the years ahead.
- 03/10/2022
|
2 Growth Stocks That Wall Street Thinks Can Double in Value
- From biotech to blockchain, there is no shortage of growth opportunities here.
- 02/24/2022
|
Is This SPAC a Buy After Falling More Than 50%?
- Ginkgo Bioworks is still a story stock and one that's expensive to buy into.
- 02/18/2022
|
7 Stocks to Buy After Sentiment Slipped to Lows
- With sentiment souring over inflation and other concerns, contrarians may have an opportunity to bank on certain stocks to buy like these. The post 7 Stocks to Buy After Sentiment Slipped to Lows appeared first on InvestorPlace.
- 02/17/2022
|
Ginkgo Bioworks Announces Participation in Upcoming Conferences
- BOSTON, Feb. 8, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in the following upcoming conferences: BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 15, 2022, at 10:00 a.m. ET SVB Leerink 11th Annual Global Healthcare Conference on Friday, February 18, 2022, at 10:40 a.m.
- 02/08/2022
|
Best Penny Stocks to Buy Next Month? Check These 3 Out
- Can these penny stocks push up next month? The post Best Penny Stocks to Buy Next Month?
- 01/28/2022
|
Why BofA Sees 'Better Entry Point' In Ginkgo Bioworks Stock
- Ginkgo Bioworks Holdings Inc DNA is “at the forefront of the rising SynBio wave, a market we think holds much long-term promise,” according to BofA Securities. The Ginkgo Bioworks Analyst: Derik de Bruin initiated coverage of Ginkgo Bioworks with a Buy rating and $8 price target.
- 01/28/2022
|
Andreas Halvorsen Gets in on Amylyx Pharmaceuticals' IPO
- Andreas Halvorsen (Trades, Portfolio), chief investment officer of Viking Global Investors, disclosed a stake in Amylyx Pharmaceuticals Inc. ( AMLX , Financial) late last week.
- 01/25/2022
|
Ginkgo Bioworks Announces Acquisition Of Massachusetts COVID-19 Testing Provider Project Beacon COVID-19 LLC; Terms Not Disclosed
- Acquisition to enable Ginkgo to bolster its growing biosecurity platform and provide expanded COVID-19 testing options to communities in Massachusetts and beyond BOSTON, Jan. 19, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the acquisition of Project Beacon COVID-19 LLC (Project Beacon), a Boston-based social benefit organization focused on helping to increase the capacity, availability, accessibility and affordability of COVID-19 testing. Under the terms of the deal, Ginkgo acquired Project Beacon's assets and will assume responsibility for Project Beacon's ongoing operations, providing COVID-19 monitoring tools to communities in Massachusetts and other areas.
- 01/19/2022
|
Why Ginkgo Bioworks Shares Are Trading Higher Today
- Ginkgo Bioworks Holdings Inc (NYSE: DNA) is trading higher Wednesday after the company reported preliminary unaudited 2021 revenue highlights and a business review. Ginkgo Bioworks said it expects to meet or exceed its key 2021 full-year targets for the commencement of new cell programs and revenue from its cell programming and biosecurity offerings based on its preliminary unaudited estimates.
- 01/12/2022
|
Ginkgo Bioworks Holdings, Inc. (DNA) Could Find Support Soon, Here's Why You Should Buy the Stock Now
- Ginkgo Bioworks Holdings, Inc. (DNA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- 01/11/2022
|
Cathie Wood's ARK Invest Buys Over 2.1 Million Shares of Ginkgo Bioworks
- A couple of ARK Invest exchange-traded funds run by ETF star Cathie Wood made a huge buy on Thursday.
- 01/07/2022
|
Ginkgo Bioworks: World's First Synthetic Biology Syndicate
- Ginkgo has had a lackluster stock performance since IPO. I believe there is intrinsic value in their technology and financing.
- 01/03/2022
|
Cathie Wood's ARK Invest Buys Nearly 1.5 Million Shares of Ginkgo Bioworks
- A couple of ARK Invest exchange-traded funds run by ETF star Cathie Wood made a huge buy on Wednesday.
- 12/02/2021
|
Andreas Halvorsen Dives Into Ginkgo Bioworks, Adds to Humana
- Viking Global leader Andreas Halvorsen (Trades, Portfolio) disclosed his portfolio for the third quarter in November.
- 12/01/2021
|
50% Pop Coming For Planet Labs
- 50% Pop Coming For Planet Labs
- 11/30/2021
|
Ginkgo Bioworks Holdings, Inc. (DNA) CEO Jason Kelly on Q3 2021 Results - Earnings Call Transcript
- Ginkgo Bioworks Holdings, Inc. (DNA) CEO Jason Kelly on Q3 2021 Results - Earnings Call Transcript
- 11/15/2021
|
Selecta Biosciences, Ginkgo Bioworks Join Forces To Develop Rare Disease Treatments
- Selecta Biosciences Inc (NASDAQ: SELB) and Ginkgo Bioworks Holdings Inc (NYSE: DNA) have collaborated to design novel and improved therapeutic potential enzymes for orphan and rare diseases. The partnership will leverage Ginkgo's cell programming platform and Selecta's ImmTOR platform to create potentially transformative enzymatic therapies.
- 10/26/2021
|
Baillie Gifford Trimmed Positions In Alibaba, Tesla, Nio, Moderna In Q3, Here's What It Bought Instead
- Investment firm Baillie Gifford lowered exposure in Tesla Inc (NASDAQ:TSLA), Alibaba Group Holding (NYSE:BABA) and Nio Inc (NYSE:NIO) in the third quarter and snapped up shares in vaccine maker Moderna Inc (NASDAQ:MRNA) and Ginkgo Bioworks Holdings (NYSE:DNA) instead, regulatory filings reveal. What Happened: Baillie Gifford, a 110-year-old asset management firm and an early investor in Tesla, sold 1.99 million shares in the Elon Musk-led electric vehicle maker in the third quarter, reducing its holdings in the company by 12.5% from the previous quarter.
- 10/21/2021
|
Why Shares of Ginkgo Bioworks Plunged Today
- A new project in the Lone Star state wasn't enough to convince the bears to hold on to their shares.
- 10/20/2021
|
Ginkgo Bioworks Investor Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ginkgo Bioworks To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - October 18, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ginkgo Bioworks Holdings, Inc. ("Ginkgo Bioworks" or the "Company") (NYSE: DNA).If you suffered losses exceeding $50,000 investing in Ginkgo Bioworks stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click...
- 10/18/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ginkgo Bioworks Holdings, Inc. - DNA
- NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ginkgo Bioworks Holdings, Inc. ("Ginkgo" or the "Company") (NYSE: DNA). Such investors are advised to contact Robert S.
- 10/15/2021
|
Ginkgo Bioworks Shareholder Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ginkgo Bioworks To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - October 15, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ginkgo Bioworks Holdings, Inc. ("Ginkgo Bioworks" or the "Company") (NYSE: DNA).If you suffered losses exceeding $50,000 investing in Ginkgo Bioworks stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here...
- 10/15/2021
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ginkgo Bioworks Holdings, Inc. and Encourages Investors with Losses to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - October 15, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ginkgo Bioworks Holdings, Inc. ("Ginkgo" or "the Company") (NYSE: DNA) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Ginkgo is the subject of a report published by Scorpion...
- 10/15/2021
|
Ginkgo Bioworks Investor Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ginkgo Bioworks To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - October 14, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ginkgo Bioworks Holdings, Inc. ("Ginkgo Bioworks" or the "Company") (NYSE: DNA).If you suffered losses exceeding $50,000 investing in Ginkgo Bioworks stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here...
- 10/14/2021
|
Ginkgo Bioworks Price Predictions: Why One Analyst Thinks Hard-Hit DNA Stock Can Hit $14.50
- Today, a bullish analyst price target placed on Ginkgo Bioworks has sent DNA stock on a nice ride as investors pile into this growth play. The post Ginkgo Bioworks Price Predictions: Why One Analyst Thinks Hard-Hit DNA Stock Can Hit $14.50 appeared first on InvestorPlace.
- 10/14/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Ginkgo Bioworks (DNA) Investors to Contact Firm's Attorneys Now, Firm Investigating Possible Securities Law Violations
- San Francisco, California--(Newsfile Corp. - October 13, 2021) - Hagens Berman urges Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) investors with significant losses to submit your losses now.Visit: www.hbsslaw.com/investor-fraud/DNA Contact An Attorney Now: DNA@hbsslaw.com 844-916-0895Ginkgo Bioworks Holdings, Inc. (DNA) Investigation: Ginkgo Bioworks is a synthetic biology company that uses a cell programming platform called "Ginkgo Foundry" to assist companies in finding more effective ways to create products.The company...
- 10/13/2021
|
Never Mind Ginkgo Bioworks' Drama -- This Synthetic Biology Stock Is Still a Buy
- If the latest short-seller attack on Ginkgo Bioworks has you nervous about synthetic biology, consider the industry leader.
- 10/13/2021
|
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Ginkgo Bioworks Holdings, Inc. and Encourages Investors with Losses to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - October 12, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ginkgo Bioworks Holdings, Inc. ("Ginkgo" or "the Company") (NYSE: DNA) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Ginkgo is the subject of a report published by Scorpion...
- 10/12/2021
|
DNA Stock: The Bull Call That Has Ginkgo Bioworks Bouncing Back After Last Week's “Scam” Accusation
- Ginkgo Bioworks (DNA) stock is doing well on Tuesday as it recovers with new coverage from an analyst with a bull stance. The post DNA Stock: The Bull Call That Has Ginkgo Bioworks Bouncing Back After Last Week's “Scam” Accusation appeared first on InvestorPlace.
- 10/12/2021
|
GINKGO BIOWORKS INVESTIGATION: Block & Leviton Is Investigating Ginkgo Bioworks Holdings For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
- Boston, Massachusetts--(Newsfile Corp. - October 12, 2021) - Block & Leviton is investigating Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) for potential securities law violations. Investors who have lost money in their Ginkgo Bioworks Holdings, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/dna.What is this all about?Earlier today, short seller Scorpion Capital released a report alleging that Ginkgo Bioworks Holdings is a "colossal...
- 10/12/2021
|
Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought
- All three of these growth stocks have been tumbling, but that doesn't frighten off ARK Invest's top stock picker.
- 10/12/2021
|
Ginkgo Bioworks Investor Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ginkgo Bioworks To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - October 11, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ginkgo Bioworks Holdings, Inc. ("Ginkgo Bioworks" or the "Company") (NYSE: DNA).If you suffered losses exceeding $50,000 investing in Ginkgo Bioworks stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here...
- 10/11/2021
|
INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Ginkgo Bioworks Holdings, Inc. and Encourages Investors with Losses to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - October 11, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ginkgo Bioworks Holdings, Inc. ("Ginkgo" or "the Company") (NYSE: DNA) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Ginkgo is the subject of a report published by Scorpion...
- 10/11/2021
|
Cathie Wood's Ark Invest Piles Up Another $15.8M In Gingko On Dip Amid Short-Seller Allegations
- Cathie Wood-led Ark Invest on Friday snapped up more shares in Ginkgo Bioworks Holdings Inc (NYSE: DNA) on the dip. The popular money manager's investment firm snapped up 1.53 million shares — estimated to be worth $15.86 million — in the synthetic biology stock that was hit hard last week by two back-to-back short-seller reports that called the company a “colossal scam” and “a scheme.
- 10/11/2021
|
DNA Investor Alert: Thornton Law Firm Announces Investigation
- Boston, Massachusetts--(Newsfile Corp. - October 9, 2021) - The Thornton Law Firm alerts investors that it is investigating Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) for potential securities violations. Investors who currently own shares or options of DNA may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/Ginkgo for more information. Investors may also email investors@tenlaw.com or call 617-531-3917. FOR MORE INFORMATION: www.tenlaw.com/cases/GinkgoOn October 6, 2021, short seller Scorpion Capital released a report...
- 10/09/2021
|
INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Ginkgo Bioworks Holdings, Inc. and Encourages Investors with Losses to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - October 8, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ginkgo Bioworks Holdings, Inc. ("Ginkgo" or "the Company") (NYSE: DNA) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Ginkgo is the subject of a report published by Scorpion...
- 10/08/2021
|
Ginkgo Bioworks Shareholder Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ginkgo Bioworks To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - October 8, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ginkgo Bioworks Holdings, Inc. ("Ginkgo Bioworks" or the "Company") (NYSE: DNA).If you suffered losses exceeding $50,000 investing in Ginkgo Bioworks stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here...
- 10/08/2021
|
Ginkgo Investigation Alert: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) Investors
- RADNOR, Pa., Oct. 8, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of shareholders of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo") f/k/a Soaring Eagle Acquisition Corp. (Nasdaq: SRNG) ("Soaring Eagle").
- 10/08/2021
|
EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Ginkgo Bioworks Holdings, Inc.
- New York, New York--(Newsfile Corp. - October 8, 2021) - Levi & Korsinsky notifies investors that it has commenced an investigation of Ginkgo Bioworks Holdings, Inc. ("Ginko Bioworks" or the "Company") (NYSE: DNA) concerning possible violations of federal securities laws.On October 6, 2021, Scorpion Capital published a report about Ginkgo alleging that it is a "colossal scam." It describes the Company's business model is a "shell game," and that the company is highly dependent on...
- 10/08/2021
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ginkgo Bioworks Holdings, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, Oct. 8, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ginkgo Bioworks Holdings, Inc. ("Ginkgo" or "the Company") (NYSE: DNA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/08/2021
|
GINKGO ALERT: Bragar Eagel & Squire, P.C. is Investigating Ginkgo Bioworks Holdings, Inc. on Behalf of Ginkgo Stockholders and Encourages Investors to Contact the Firm
- NEW YORK--(BUSINESS WIRE)-- #action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Ginkgo Bioworks Holdings, Inc. (“Ginkgo” or the “Company”) (NYSE: DNA) on behalf of Ginkgo stockholders. Our investigation concerns whether Ginkgo has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. Ginkgo develops platform for cell programming. Its platform is
- 10/07/2021
|
DNA BREAKING NEWS: ROSEN, LEADING INVESTOR COUNSEL, Encourages Ginkgo Bioworks Holdings, Inc. Investors with Losses to Inquire About Class Action Investigation - DNA
- NEW YORK, Oct. 7, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) resulting from allegations that Ginkgo may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Ginkgo securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 10/07/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ginkgo Bioworks Holdings, Inc. - DNA
- NEW YORK, Oct. 7, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ginkgo Bioworks Holdings, Inc. ("Ginkgo" or the "Company") (NYSE: DNA). Such investors are advised to contact Robert S.
- 10/07/2021
|
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Ginkgo Bioworks Holdings, Inc. and Encourages Investors with Losses to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - October 7, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ginkgo Bioworks Holdings, Inc. ("Ginkgo" or "the Company") (NYSE: DNA) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Ginkgo is the subject of a report published by Scorpion...
- 10/07/2021
|
Thornton Law Firm Announces Investigation Into DNA
- Boston, Massachusetts--(Newsfile Corp. - October 7, 2021) - The Thornton Law Firm alerts investors that it is investigating Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) for potential securities violations. Investors who currently own shares or options of DNA may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/Ginkgo for more information. Investors may also email investors@tenlaw.com or call 617-531-3917. FOR MORE INFORMATION: www.tenlaw.com/cases/GinkgoOn October 6, 2021, short seller Scorpion Capital released a report...
- 10/07/2021
|
EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Ginkgo Bioworks Holdings, Inc.
- New York, New York--(Newsfile Corp. - October 7, 2021) - Levi & Korsinsky notifies investors that it has commenced an investigation of Ginkgo Bioworks Holdings, Inc. ("Ginko Bioworks" or the "Company") (NYSE: DNA) concerning possible violations of federal securities laws. On October 6, 2021, Scorpion Capital published a report about Ginkgo alleging that it is a "colossal scam." It describes the Company's bus
- 10/07/2021
|
Ginkgo Bioworks Investor Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ginkgo Bioworks To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - October 7, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ginkgo Bioworks Holdings, Inc. ("Ginkgo Bioworks" or the "Company") (NYSE: DNA).If you suffered losses exceeding $50,000 investing in Ginkgo Bioworks stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here...
- 10/07/2021
|
DNA Investigation Alert: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) Investors
- RADNOR, Pa.--(BUSINESS WIRE)---- $DNA--Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) Investors
- 10/07/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Ginkgo Bioworks (DNA) Investors to Contact Firm's Attorneys Now, Firm Investigating Possible Securities Law Violations
- SAN FRANCISCO, Oct. 7, 2021 /PRNewswire/ -- Hagens Berman urges Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) investors with significant losses to submit your losses now. Visit: www.hbsslaw.com/investor-fraud/DNA Contact An Attorney Now: DNA@hbsslaw.com 844-916-0895 Ginkgo Bioworks Holdings, Inc. (DNA) Investigation: Ginkgo Bioworks is a synthetic biology company that uses a cell programming platform called "Ginkgo Foundry" to assist companies in finding more effective ways to create products.
- 10/07/2021
|
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ginkgo Bioworks Holdings, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $DNA #DNA--ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ginkgo Bioworks Holdings, Inc.
- 10/07/2021
|
Cathie Wood's ARK Invest Buys Over 8 Million Shares of Ginkgo Bioworks
- A couple of ARK Invest exchange-traded funds run by ETF star Cathie Wood made a huge buy on Wednesday.
- 10/07/2021
|
Cathie Wood Sells $49.4M In Tesla And Buys $87.5M In Ginkgo Bioworks On Dip As Stock Becomes Target Of Short Sellers
- Cathie Wood-led Ark Invest on Wednesday snapped up shares in Ginkgo Bioworks Holdings Inc (NYSE: DNA) on the day the synthetic biology company stock was hit hard by two back-to-back short-seller reports that called the company a “colossal scam” and “a scheme.” The popular money manager bought 8.26 million shares — estimated to be worth $87.5 million — in the Boston, Massachusetts-based biotech company.
- 10/06/2021
|
Ademi LLP Investigates Claims of Securities Fraud against Ginkgo Bioworks Holdings, Inc.
- MILWAUKEE, Oct. 6, 2021 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Ginkgo (NYSE:DNA). The investigation results from inaccurate statements Ginkgo may have made regarding its business operations and prospects.
- 10/06/2021
|
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Ginkgo Bioworks Holdings, Inc. (DNA) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)---- $DNA #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Ginkgo Bioworks Holdings, Inc. (“Ginkgo” or the “Company”) (NYSE: DNA) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Ginkgo investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securi
- 10/06/2021
|
The Law Offices of Frank R. Cruz Announces Investigation of Ginkgo Bioworks Holdings, Inc. (DNA) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)---- $DNA #investors--The Law Offices of Frank R. Cruz Announces Investigation of Ginkgo Bioworks Holdings, Inc. (DNA) on Behalf of Investors
- 10/06/2021
|
SHAREHOLDER ALERT: Investigation of Ginkgo Bioworks Holdings, Inc. Announced by Holzer & Holzer, LLC
- Atlanta, Georgia--(Newsfile Corp. - October 6, 2021) - Holzer & Holzer, LLC is investigating whether Ginkgo Bioworks Holdings, Inc. ("Ginkgo" or the "Company") (NYSE: DNA) complied with federal securities laws. On October 6, 2021, Scorpion Capital released a report alleging, among other things, the Company is highly dependent on related party transactions. On this report, the price of the Company's stock declined.If you purchased Ginkgo stock and suffered a substantial loss on that investment, you...
- 10/06/2021
|
INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Ginkgo Bioworks Holdings, Inc. and Encourages Investors with Losses to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - October 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ginkgo Bioworks Holdings, Inc. ("Ginkgo" or "the Company") (NYSE: DNA) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Ginkgo is the subject of a report published by Scorpion...
- 10/06/2021
|
EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Ginkgo Bioworks Holdings, Inc.
- New York, New York--(Newsfile Corp. - October 6, 2021) - Levi & Korsinsky notifies investors that it has commenced an investigation of Ginkgo Bioworks Holdings, Inc. ("Ginko Bioworks" or the "Company") (NYSE: DNA) concerning possible violations of federal securities laws.On October 6, 2021, Scorpion Capital published a report about Ginkgo alleging that it is a "colossal scam." It describes the Company's business model is a "shell game," and that the company is highly dependent on...
- 10/06/2021
|
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Ginkgo Bioworks Holdings, Inc. (DNA) on Behalf of Investors
- BENSALEM, Pa.--(BUSINESS WIRE)---- $DNA #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of Ginkgo Bioworks Holdings, Inc. (“Ginkgo” or the “Company”) (NYSE: DNA) investors concerning the Company's possible violations of federal securities laws. On October 6, 2021, Scorpion Capital published a 175-page research report alleging that Ginkgo Bioworks is a "colossal scam" and that its business model is a "shell game." According to the report, Ginkgo Bioworks is highly dependent on relate
- 10/06/2021
|
DNA Stock: 7 Things to Know About the Short Report Hammering Ginkgo Bioworks
- Today, Ginko Bioworks and DNA stock are firmly in the sights of short-sellers as various claims are made about an elaborate fraud underway. The post DNA Stock: 7 Things to Know About the Short Report Hammering Ginkgo Bioworks appeared first on InvestorPlace.
- 10/06/2021
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ginkgo Bioworks Holdings, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $DNA #DNA--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ginkgo Bioworks Holdings, Inc.
- 10/06/2021
|
Ginkgo Bioworks Stock Drops 20% After Short Sellers Call Company A 'Colossal Scam'
- Shares of synthetic biology company Ginkgo Bioworks Holdings Inc (NYSE:DNA) traded lower by more than 20% on Wednesday. What Happened?
- 10/06/2021
|
Here's Why This Cathie Wood Stock Is Crashing Today
- Scorpion Capital is shooting some venom at a new target today.
- 10/06/2021
|
Ginkgo Bioworks plunges 24% after short-seller calls it a 'Frankenstein mash-up of the worst frauds'
- The decline in Ginkgo hurts investors like Ark Invest, which owned a combined $325 million stake in two of its ETFs.
- 10/06/2021
|
DNA INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Ginkgo Bioworks Holdings, Inc. Investors with Losses to Inquire About Class Action Investigation – DNA
- NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) resulting from allegations that Ginkgo may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Ginkgo securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang
- 10/06/2021
|
Here's an Up-and-Coming Biotech Stock to Watch With a Cannabis Connection
- And it has a really great ticker that many other biotechs might envy.
- 10/02/2021
|
Power & Digital Infrastructure Acquisition Corp. Warrants: Shareholders Approval In 4Q 2021 Will Unlock Significant Upside
- Power & Digital Infrastructure Acquisition Corp. Warrants: Shareholders Approval In 4Q 2021 Will Unlock Significant Upside
- 09/28/2021
|
Andreas Halvorsen Discloses Stake in Ginkgo Bioworks Following Market Debut
- Seeing a potential value opportunity in a newly public company, Viking Global leader Andreas Halvorsen (Trades, Portfolio) disclosed a stake in Ginkgo Bioworks Holdings Inc. ( DNA , Financial) earlier this week.
- 09/28/2021
|
7 Companies Set to IPO That Could Be the Next Big Thing
- While the market for IPOs is always risky and unpredictable, it's an enticing sector that can potentially facilitate massive gains. The post 7 Companies Set to IPO That Could Be the Next Big Thing appeared first on InvestorPlace.
- 09/24/2021
|
7 Healthcare Stocks to Buy Now as the Pandemic Forces a Rethink
- Thanks to the coronavirus pandemic, many people are rethinking the medical sector, boding well for healthcare stocks. The post 7 Healthcare Stocks to Buy Now as the Pandemic Forces a Rethink appeared first on InvestorPlace.
- 09/22/2021
|
Why Shares of Ginkgo Bioworks Are Rising Today
- A new analyst rating has investors excited.
- 09/21/2021
|
As Synthetic Biology Company Ginkgo Bioworks Starts Trading, Its Five Founders Briefly Become Billionaires
- Some 400 Ginkgo Bioworks employees traveled to NYC to celebrate the company's first day of trading on the NYSE. Many were now millionaires, while Ginkgo's five founders' stakes approached $1 billion each at day's end.
- 09/17/2021
|
Toy Shortage Christmas 2021: 11 Things Consumers and Investors Can Expect
- A Christmas toy shortage for 2021 seems likely as retailers struggle to get enough inventory for the upcoming holiday shopping season. The post Toy Shortage Christmas 2021: 11 Things Consumers and Investors Can Expect appeared first on InvestorPlace.
- 09/17/2021
|
DNA Stock Cooks Up 10% Gains on Ginkgo Biowork's First Trading Day
- Ginkgo Bioworks knows about growth and so far, it seems as though DNA stock does as well as it kicks off under an aptly titled ticker. The post DNA Stock Cooks Up 10% Gains on Ginkgo Biowork's First Trading Day appeared first on InvestorPlace.
- 09/17/2021
|
Ginkgo Bioworks CEO Jason Kelly on the business of programmable DNA
- Ginkgo Bioworks CEO Jason Kelly sat down with CNBC's Morgan Brennan on 'Squawk on the Street' to explain what their company does, a peak at their financials and exploring potential growth opportunities for the company.
- 09/17/2021
|
SRNG, DNA: 14 Things to Know About Ginkgo Bioworks and the Soaring Eagle SPAC Merger
- Ginkgo Bioworks (DNA) stock is set to start trading today as the company completes its merger with SPAC Soaring Eagle (SRNG). The post SRNG, DNA: 14 Things to Know About Ginkgo Bioworks and the Soaring Eagle SPAC Merger appeared first on InvestorPlace.
- 09/17/2021
|
